

Overview

A Review of the Effects of Pain and Analgesia on Immune System Function and Inflammation: Relevance for Preclinical Studies

George J DeMarco^{1*} and Elizabeth A Nunamaker²

One of the most significant challenges facing investigators, laboratory animal veterinarians, and IACUCs, is how to balance appropriate analgesic use, animal welfare, and analgesic impact on experimental results. This is particularly true for in vivo studies on immune system function and inflammatory disease. Often times the effects of analgesic drugs on a particular immune function or model are incomplete or don't exist. Further complicating the picture is evidence of the very tight integration and bidirectional functionality between the immune system and branches of the nervous system involved in nociception and pain. These relationships have advanced the concept of understanding pain as a protective neuroimmune function and recognizing pathologic pain as a neuroimmune disease. This review strives to summarize extant literature on the effects of pain and analgesia on immune system function and inflammation in the context of preclinical in vivo studies. The authors hope this work will help to guide selection of analgesics for preclinical studies of inflammatory disease and immune system function.

Abbreviations and acronyms: CB, Endocannabinoid receptor; CD, Crohn disease; CFA, Complete Freund adjuvant; CGRP, Calcitonin gene-related peptide; COX, Cyclooxygenase; CTL, Cytotoxic T-Lymphocytes; DAMP, Damage-associated molecular pattern molecules; DRG, Dorsal root ganglion; DSS, Dextran sodium sulphate; ECS, Endocannabinoid system; IBD, Inflammatory bowel disease; IFA, Incomplete Freund adjuvant; Las, Local anesthetics; PAMP, Pathogen-associated molecular pattern molecules; PGE₂, Prostaglandin E₂; P2Y, ATP purine receptor Y; P2X, ATP purine receptor X; TNBS, 2,4,6-Trinitrobenzene sulphonic acid; TRP, Transient receptor potential ion channels; TRPV, Transient Receptor Potential Vanilloid; TG, Trigeminal ganglion; UC, Ulcerative colitis

DOI: 10.30802/AALAS-CM-19-000041

The immune system is comprised of 2 arms, innate and adaptive immunity, which function in concert to protect an organism from pathogens and toxins. The immune system also plays an integral role in the process of tissue repair after injury.^{58,127} The process by which the immune system responds to pathogens, toxins, and tissue injury and initiates tissue repair is known as inflammation. Inflammation and its association with pain have been recognized since it was first described by the Roman, Aulus Celsus.¹⁷⁷ More recently, it has been elucidated that the immune and nervous systems interact to mediate and modulate central and peripheral nociceptive processes that influence acute and chronic pain.^{69,95,190,217} There is a dizzying array of cells, receptors, enzymes, cytokines, peptides, and neurotransmitters that constitute the inflammatory process and neuroimmune interactions related to pain. To further complicate the picture, drugs that are used to control pain, modulate immune function and the immune system can produce endogenous analgesics.^{129,200} The goal of this article is to improve the reader's understanding of the relationship between pain, analgesia, and

immune function in the context of preclinical in vivo studies. We hope this article will serve as a guide for laboratory animal professionals, IACUCs, and investigators in the selection of appropriate analgesics for preclinical studies of inflammatory disease and immune system function.

Neuroimmune Interactions

With regards to pain and analgesia, it is critical to understand the complex interactions between the immune and nervous systems. It has been postulated that a well-regulated neuroimmune response to infection, noxious stimuli, and tissue injury represents a cohesive system for host defense and tissue healing.³⁶ Thus, conceptual siloing of immune and nervous system responses to pain is no longer appropriate.

Neurogenic Inflammation

Multiple lines of evidence indicate that nociceptive neurons can initiate and modulate inflammation. Considering the speed at which they respond to any form of insult, (traumatic, thermal, chemical) and their broad tissue distribution, nociceptive neurons are uniquely poised to function as monitors and rapid initiators of a neuroimmune response.³⁶ When triggered by noxious stimuli or alarmins (ATP, uric acid, hydroxynonenals) from damaged tissue, receptors primarily in the Transient Receptor

Received: 01 Apr 2019. Revision requested: 29 May 2019. Accepted: 07 Aug 2019.
Department of ¹Animal Medicine, University of Massachusetts Medical School, Worcester, Massachusetts; ²Animal Care Services, University of Florida, Gainesville, Florida

*Corresponding author. Email: george.demarco@umassmed.edu




Figure 1. Interactions between nociceptive neurons and microglial cells after neuronal damage or activation by alarmins are depicted. l-glutamate (l-glu), substance P (SubP), adenosine triphosphate (ATP), brain-derived neurotrophic factor (BDNF), cysteine-cysteine chemokine ligand CCL2 neurokinin-1 receptors (NK-1R), extracellular signal-regulated kinase (ERK), α -amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptors (AMPA), cyclic adenosine monophosphate response element binding protein (CREB). ATP purinergic receptors, (P2X₇, P2Y₁₂ and P2Y₁₃), mitogen-activated kinase (p38), c-jun-N terminal kinase (JNK), nuclear factor kappa B (NF κ B), Interleukin-1 β (IL1 β) and its receptor, (IL-1R) tumor necrosis factor α (TNF α) and its receptor (TNFR), chloride (Cl⁻) transporter (KCC2), gamma aminobutyric acid A receptor (GABA_A), chemokine ligand 2 (CCL2), chemokine receptor 2,3 (CCR2, CCR3), Cathepsin S (CatS), fractalkine (FKN, also termed CX3C-chemokine ligand 1), chemokine receptor 1 (CX3CR), Matrix metalloprotease 2, 9 (MMP2 MMP9), toll-like receptor 4 (TLR4).

Reprinted by permission from Wolters Kluwer Health. Central neuron-glia interactions and neuropathic pain, Eduardo E. Benarroch 2010

Potential ion channels (TRP) and ATP Purine Receptor X (P2X) and Y (P2Y) family activate nociceptors which release neuropeptides that initiate a response referred to as neurogenic inflammation.^{36,95} Specifically, tachykinins (substance P and neurokinin A) and calcitonin gene-related peptide (CGRP), released from nociceptive neurons, act on vascular endothelium and smooth muscle cells, causing vasodilation and increased endothelial permeability.^{16,116,143,174,179,185} Activated nociceptive neurons also release neuropeptides and cytokines which attract and activate innate and adaptive immune cells.^{65,85,86,104,187,219} Over a course of days, the inflammatory response recruits monocytes, which differentiate into macrophages. Over time, macrophages undergo phenotype changes from inflammatory/host defense (M1) to antiinflammatory/wound healing (M2) cells as the wound microenvironment changes.^{58,127} Thus, nociceptor activation can induce the factors that cause the classic signs of inflammation: rubor, tumor, calor, and dolor, and may contribute to wound healing.

Bidirectional Interactions

Interactions between the immune system and nervous system are bidirectional and not all nociceptor driven. Nociceptive neurons express and respond to a receptor profile similar to that of leukocytes. These include receptors for cytokines, eicosanoids

(prostaglandins), Toll-like receptors, and ATP purine receptors P2X and P2Y.^{76,147,209,214} Leukocytes express TRP receptors, macrophages, express high levels of Transient Receptor Potential Vanilloid (TRPV2), and mast cells express TRPV1. To further complicate the picture, both leukocytes and nociceptors express μ , δ , and κ opioid receptors, and T-lymphocytes, granulocytes and monocytes-macrophages can release endogenous opioid peptides.^{129,133,154,200}

The pattern of aforementioned receptor expression suggests that the immune system can modulate nociception, and the nervous system can modulate inflammation. Nociceptors can also be directly activated by infectious agents, damage-associated molecular pattern molecules (DAMPs) and pathogen-associated molecular pattern molecules (PAMPs) through Toll-like receptors.^{35,59,146,214} It has been well established that inflammatory mediators activate nociceptors (causing pain) and can initiate neural plasticity in nociceptive pathways. This results in peripheral and central nociceptor sensitization.^{15,43,199} Clinically, peripheral and central nociceptor sensitization manifests as allodynia, hyperesthesia, and hyperalgesia.²⁰⁸

Neuroimmune activation of nociceptive neurons occurs in the PNS and CNS. In response to injury or alarmin stimulation, leukocytes, endothelial cells, and neurons in the dorsal root ganglion (DRG), trigeminal ganglia (TG) and the dorsal horn of the spinal cord release eicosanoids, growth factors, kinins, and cytokines.^{120,121,173,223} This milieu of biochemicals binds to receptors on nociceptive neurons, which are coupled to TRPV receptors and ion channels, resulting in increased neuron activity and sensitization.^{110,111,164,199,206,208}

Microglial Activation

Activation and proliferation of microglial cells is thought to be a central feature of the neuroimmune interface both in physiologic and pathologic pain, and a primary element in the development of central sensitization and potentially, chronic pain (Figure 1).²¹⁶ Microglia are the predominant cell type in the CNS, and reside at a critical interface; the synapse between 1st and 2nd order nociceptive neurons in the spinal dorsal horn. The activation of microglia represents a key feature of the neuroimmune interface, since activation can occur through neuronal, immune and pathogen mediated pathways.^{49,96,217} In addition, sex differences in glial activation have been reported, which may contribute to the established sexual dimorphism of pain.^{49,134}

Microglia are activated by ATP, CC-chemokine ligand 2 and 21, CX₃CL1 (fractalkine), and neuregulin 1, released from 1st order neurons during high threshold activation or injury.^{148,212} Of particular note is that the receptor for CX₃CL1, CX₃CR1, is only expressed on microglia and may represent a unique neuroimmune interface.²¹² Pathogens, DAMPs and PAMPs can directly activate microglial cells through binding to Toll-like receptors.^{72,184} Cytokines released from leukocytes both activate microglial cells and directly contribute to nociceptive hyperactivity. When activated, microglia release proinflammatory cytokines, reactive oxygen species, brain-derived neurotrophic factor, and integrins. This biochemical barrage results in enhanced excitability in 2nd order neurons, increased release of substance P, glutamate and excitatory amino acids from primary afferent neurons, astrocyte activation, inhibition of inhibitory interneurons and recruitment of T-cells.²¹⁶

Endocannabinoid System

The Endocannabinoid system (ECS), an endogenous "on-demand" messaging system comprised of lipophilic ligands,

their receptors, and synthetic proteins, represents another neuro-immune interface.¹⁶⁷ The ECS has widespread and varied physiologic functions throughout the body including neuro-immune modulatory effects. The 2 principle endocannabinoid receptors (CB) are CB₁ and CB₂. CB₁ receptors are found primarily in presynaptic neurons and are abundant in peripheral and central nociceptive pathways.^{1,82,83,102} CB₂ receptors are expressed at lower levels in neurons and principally reside in peripheral tissues and leukocytes, including microglia.¹⁶² While CB₁ expression appears constitutive in the CNS, CB₂ is highly induced by inflammation and tissue injury.^{20,21,40,41,125} However, it remains unclear if the increase in CB₂ is due to increased expression in resident leukocytes or due to infiltration from CB₂ expressing monocytes. In response to high levels of activity, the primary endocannabinoid ligands 2-arachidonoylglycerol and arachidonylethanolamide are synthesized from membrane phospholipids in postsynaptic neurons.^{4,45,222} Glial cell production of endocannabinoids has also been demonstrated in vitro, and is postulated to occur during neuronal injury.^{32,52} Ligand binding to CB_{1r} results in antinociception by activation of descending antinociceptive pathways and inhibition of nociceptive neurotransmission and supraspinal processing.^{1,82,102,139,153} Cannabinoids exert broad antiinflammatory effects on peripheral leukocytes and glial cells, including reduced proinflammatory cytokine release, increased antiinflammatory cytokine release, decreased cell migration and activation, and inducing apoptosis.^{30,167}

Effect of Pain on Immune System Function

Clearly, the nervous and immune systems are inexorably linked. However, separating the effect of pain resulting from tissue injury and the direct effect of tissue damage on immune function can be problematic. In addition, the effects of chronic pain on immune system function are significantly different than the effects of acute pain, and often involves a chronic inflammatory stimulus. Experimental procedures that employ noxious stimuli which do not (or should not) cause tissue damage have been shown to suppress selective immune function. For example, foot shock has been shown to suppress NK cell activity and mitogen induced cell proliferation.^{172,183,193} Suppression of antigen stimulated IgG production and a reduced in vitro proliferative response to alloantigens (as assessed by mixed lymphocyte reaction) has been demonstrated in a tail-shock model.^{63,112} These studies suggest the possibility that pain or aversion (stress) induce the release of immunosuppressive hormones that modulate immune function in these models.

Surgery

Surgical procedures have well documented and marked effects on immune system function in humans, including increased susceptibility to infection, delayed wound healing, and enhanced tumor growth and spread of metastatic cancer.^{44,77,135} Similar data exists in animal models. Reduced NK and B-cell and T- cell activity and enhanced tumor growth have been demonstrated in rat and mouse surgical model.^{7,19,159,168,186,204,205} Impairment of macrophage function, including reduced phagocytosis of pathogens, microbicidal activity and H₂O₂ release and seemingly paradoxical increased TNF α release has been shown after surgical procedures in rodents.^{92,142,149,189} Macrophage dysfunction shows a phasic response over time in surgical models and decreased antigen presentation can last for a week.¹⁴² T-cell dysfunction characterized, by decreased production of IL2, IFN γ , and loss of T cell receptor – ζ occurs after laparotomy in mice, and may be due to T-cell suppression by myeloid CD11b⁺/

Gr-1⁺ cells that infiltrate the spleen after surgery.¹³² Serum levels of the proinflammatory cytokines IL6 and IL1 β transiently increase after laparotomy, and the potent angiogenic cytokine Vascular Endothelial Growth Factor, implicated in enhanced tumor growth, increases significantly around 6 to 12 d after surgery.¹⁶⁸ Seven days after surgical trauma and hemorrhage, there is a shift in splenic T-helper cytokine profiles from Th1 (decreased IFN γ , IL2) to Th2 (increased IL4, IL5, IL6, and IL10) in mouse.¹³⁰ Shifts in Th1 to Th2 phenotypes are associated with increased susceptibility to viral, bacterial and helminth infections and the development of sepsis.^{87,105} In addition, the effects of the surgical trauma and hemorrhage protocol on immune function are more pronounced in 18 to 20 mo old animals compared with 6 to 8 wk old.⁹⁸

The mechanisms underlying immunosuppression in surgery and trauma models are complex and involve, pain, activation of the Hypothalamic-Pituitary-Axis, sympathetic nervous system activation, tissue trauma, and the effects of anesthesia and analgesia.^{81,105,107} Despite evidence that analgesics can inhibit immune function, a significant body of research suggests that robust pain management in humans reduces surgically related immunosuppression.^{3,9,17,18,97,192,225, 227} Although not as extensive as the human literature, similar findings have been made in rodents, which suggest that surgical pain management improves immune function and reduces tumor spread.^{14,74,165,166,192}

Analgesic Modulation of Immune Function. Opioids. Opioids are some of the most common and potent analgesics used in laboratory animal medicine and in vivo research. Considerable effort has gone into elucidating the effects of opioids on immune function, however, the exact mechanism by which opioids modulate immune function has not been clearly elucidated. Postulated mechanisms for opioid modulation of immune function include alterations in the Hypothalamic-Pituitary-Axis, mu-opioid receptor activation, drug binding to nonopioid receptors on leukocytes, modulation of autonomic tone, drug structure, or a combination of effects.^{5,25} In general, opioids can be classified as drugs with mild to moderate effects on immune function (buprenorphine, hydromorphone, oxycodone, tramadol, hydrocodone, oxycodone) or marked effects on immune function (codeine, methadone, morphine, fentanyl, remifentanyl).⁵ Because the effects of opioids on immune function vary by drug and species, this discussion will examine the immune modulatory profile of each drug individually.

Buprenorphine. Arguably, buprenorphine is the most commonly used opioid in laboratory animal medicine. It appears that buprenorphine has the least effect on immune function, compared to other opioids, although not inert in this respect. When used as an analgesic in the guinea pig Sereny test (0.05 mg/kg BID for the duration of the test) buprenorphine had no effect on *Shigella* antigen induced or vaccine induced antibody responses or severity ratings.⁷³ When infused to healthy dogs for 24 h, buprenorphine (1.7 μ g/kg/h) had no effect on leukocyte stimulated cytokine production, apoptosis, neutrophil phagocytosis, or oxidative burst. Similar effects were noted for morphine.¹⁵¹

Pain induced by immunization with complete Freund adjuvant (CFA) and incomplete Freund adjuvant (IFA) in mice was reduced by buprenorphine (0.1 mg/kg BID X 72 h) and did not impair vaccine induced IgG titers.¹⁰⁸ Infusion of buprenorphine in mouse for up to 7 d at 300 μ g/day had no effect on NK cell activity and splenocyte lymphoproliferation, γ interferon release or IL2 production.¹⁴⁰ In the mouse intracranial lymphocytic choriomeningitis virus model, infusion of buprenorphine (0.15 mg/kg/d) reduced pain scores and had no effect on the numbers

of splenic CD8⁺, CD4⁺, NK1.1, and CD19⁺ cells or cytotoxic T-cell responses to viral epitopes.¹⁵⁵ CNS Infiltration of leukocytes and virus-specific cytotoxic T cells in response to infection was also not affected.¹⁵⁵ Administration of buprenorphine to mice at 2 mg/kg SID for 7 d had no effect on IgG and IgM titers in responses to sheep red blood cells, and increased the number of antibody producing cells.⁶⁰ In the same study, using a contact hypersensitivity model, a process dependent on Th-1 lymphocytes and macrophage function, buprenorphine and oxycodone were shown to suppress reactions during the induction and effector phase.⁶⁰ Nitric oxide release from macrophages was suppressed, and no significant effects on cytokine release from either unstimulated or LPS stimulated macrophages was noted.⁶⁰ Although not reported as statistically significant, macrophage surface markers were also reduced by buprenorphine treatment.⁶⁰

Buprenorphine can have strain and species dependent effects. In Lewis rat, buprenorphine reduced NK cell activity and suppressed mitogen stimulated proliferation and γ -interferon release from splenic lymphocytes in a dose-dependent fashion.³³ Suppression of immune function was noted after single doses of buprenorphine either 0.1 and 1.0 mg/kg, although not at 0.01 mg/kg. The immunosuppressive effects of buprenorphine were inhibited by administration of naltrexone, suggesting mu-receptor modulation of immune function in this study.³³ Conversely, in Fischer rats, 2 doses of buprenorphine (0.1 mg/kg) given 5 h apart, were shown to preserve NK cell function in a surgical model⁶⁴ and 0.66 nmol injected once into the midbrain had no effect on splenic NK cell, T cell, and macrophage function.⁶⁸

The advent of sustained release formulations of buprenorphine invites questions as to the potential effects of such preparations on immune function. Evidence is emerging that sustained release buprenorphine has a different immunomodulatory fingerprint and may be less immunomodulatory than buprenorphine HCl.^{6,78}

Morphine and Fentanyl. Morphine and fentanyl have well documented immunosuppressant effects in humans. Owing to their infrequent use as analgesics, the effects of morphine and fentanyl on immune function in laboratory animals is not as well established. It is clear; however, that morphine and fentanyl have different immunomodulatory profiles, despite their antinociceptive action being primarily through mu receptor binding. In the mouse, fentanyl infusion (12.5 mg/h) over 7 d resulted in significant depression of NK cell activity, lymphoproliferation and IL2 and IFN γ release at day 1 and 3 of treatment.¹⁴⁰ At day 7, immunotolerance appeared to develop, and no significant changes in the aforementioned dependent measures were noted.¹⁴⁰ Several studies in mouse have documented the suppressive effects of morphine and fentanyl on macrophage dependent humoral responses, stimulation of reactive oxygen intermediate production, and the alteration of immune responses in a contact hypersensitivity model.^{60,61} Morphine and fentanyl inhibit LPS induced TNF α release after single doses.¹⁴⁶ Repeated treatment every 8 h induces immunotolerance to morphine and sensitization to fentanyl after 6 to 8 doses.¹⁵⁰ Single doses of morphine (0.1 to 10 mg/kg) had antiinflammatory effects in a murine incision model.³⁸ However the relevance of all these findings to clinical analgesia is questionable.

Tramadol. Although not commonly used, tramadol appears to have antinociceptive effects in rodents and dog.^{122,152,182,198,230} Tramadol is considered a drug with minimal immunosuppressive activity^{11,122,182,198,230} although it can have profound antiinflammatory action and in some models be an immunostimulant.^{23,181,230}

Local Anesthetics

Local anesthetics (LAs) are extremely effective and are important drugs for pain prevention and management protocols. All LAs work through the same basic mechanism, by inhibiting voltage gated sodium channels in nociceptive neurons, blocking depolarization and thus, neurotransmission. Thus, LAs would be expected to exert an antiinflammatory effect by preventing the release of proinflammatory molecules that occurs when nociceptive neurons depolarize. Because a component of the pathophysiology of inflammatory pain is upregulation of sodium channels in nociceptive neurons, in this context, LAs inhibition of nociceptive neuron depolarization should prevent peripheral and central sensitization induced by inflammatory mediators.⁸ Most studies on LAs use lidocaine as the prototypical drug and occasionally bupivacaine, and assume comparable effects across all LAs. Leukocytes, excepting neutrophils, express voltage gated sodium channels, some of which may be important in microglia and macrophage function.⁴² The extent to which the direct inhibition of Na channels on leukocytes, interactions with other receptors such as G-protein-coupled receptors, and the indirect inhibition of inflammatory mediator release contributes to the immunomodulatory effects of LAs is not known. Another noteworthy phenomenon is that the antiinflammatory effects of LAs in vitro require supra-clinical drug concentrations and that in vivo effects occur at clinically relevant doses. LAs have been shown to modulate PMNs, macrophages, and cytokine release in a variety of models.⁸² PMN and macrophage functions (including chemotaxis, adherence, production of toxic oxygen species, phagocytosis, and cytokine release) are inhibited by LAs.^{10,12,13,70,84,191} Lidocaine has been shown to inhibit cell proliferation, cytokine production, and mitogen-activated protein kinase activation in T cells and upregulate regulatory T-cells that promote an antiinflammatory t-cell phenotype.^{84,94,101,118} One study in mouse showed that release of antiinflammatory cytokine IL10 may be enhanced by lidocaine.²¹¹ Questions remain as to how long the immunomodulatory effects of LAs persist after drug administration is complete. To date, there do not appear to be any studies that have addressed this question.

Nonsteroidal Antiinflammatory Drug (NSAID). NSAID are arguably the most commonly used class of analgesic drugs in veterinary medicine and their use is prevalent in laboratory animal medicine. All NSAID work through the same primary mechanism; the inhibition of prostaglandin synthesis by inhibition of Cyclooxygenase (COX) isoenzymes 1 and or 2. NSAID anti-inflammatory and toxic effects, mediated by inhibition of prostaglandin synthesis, is exceptionally well documented in both human and veterinary literature. However, the analgesic effects of NSAID do not seem to rely on how selective an NSAID is for COX1 or 2. Recently, a host of prostaglandin and COX independent anti-inflammatory and analgesic effects have been proposed for NSAID. These effects vary by drug, but include antioxidant activity, inhibition of Nuclear Factor- κ B, inhibition of 5-lipoxygenase, prostaglandin receptor antagonism, anti-bradykinin actions and inhibition of fatty acid amide hydrolase, cytokine release, cell adhesion, and metabolism of arachidonic acid.^{27,46,48,56,79,89,93,115,157,188} Since virtually every cell in the body constitutively expresses COX1, and COX2 can be markedly induced by inflammatory mediators, inhibition of COX has been ascribed to anti-inflammatory action in a staggering number of human and animal models. In addition, a wide range of behavioral actions have been associated with NSAID inhibition of COX.^{34,119,128,160} Data have been compiled on NSAID classified by chemical structure, COX selectivity, and putative mechanism of action. Any data on COX inhibitors must be carefully evaluated,

since COX selectivity is almost always based on *in vitro* determinations using human cells, varies depending on the type of assay employed, and may not translate from human to animal cells or from one species to another.^{47,114,115,117,176} Thus the impact of any given NSAID on immune function in a particular animal species cannot be accurately extrapolated from other NSAID or human data.

Although macrophages and neutrophils are thought to be the principle target leukocytes for NSAID actions, T cells and NK cells may also be impacted by NSAID. In neurodegenerative diseases with an inflammatory component, such as Alzheimer, the immune function of neurons, microglia, astrocytes, and endothelial cells can all be altered by NSAID.¹²³ In T cells, NSAID inhibition of COX1 interferes with T cell receptor dependent activation of p38 MAP-kinase, which blocks upregulation of COX2.¹⁶³ Both isoforms of COX and their metabolites play a significant role in the differentiation of CD4⁺ T cells to Th1, Th2, and Th17 phenotypes. In general, COX and their eicosanoid products suppress Th1 differentiation, and augment Th2 and Th17 phenotypes and function.¹¹⁷ In this fashion, NSAIDs may profoundly alter immune function, impacting a wide variety of models and processes that depend on CD4⁺ T-cell differentiation.

The effects of NSAID on immune function varies by compound and species. The following section will discuss the effect of the most commonly used NSAID drugs (carprofen, ketoprofen, meloxicam), on immune indices.

Meloxicam. In a mouse vaccination study using complete CFA, meloxicam was shown to reduce CFA associated pain without altering primary or secondary antibody responses.¹⁰⁸ In 2 separate mouse models of infectious disease, meloxicam was shown to markedly reduced release of PGE₂, TNF α , IFN γ , IL4, IL10 and increase IL2 release from splenocytes.^{144,145} Normalization of lymphoproliferation, and reduced parasitemia and mortality were noted in response to meloxicam in the *T. cruzi* study.¹⁴⁵ Meloxicam has also been shown to inhibit Nuclear Factor- κ B activation in LPS stimulated mouse macrophages.⁸⁹ Conversely, in a rabbit model of antigen induced arthritis, meloxicam was shown to decrease PGE₂, leukocyte infiltration and release of IL8 and had no effect on monocyte chemotactic peptide-1.¹²⁴ Meloxicam had no effect on LPS stimulated serum IL6 release and augmented TNF release in Guinea pig.¹⁸⁰ To date, no data has been published on immune modulation by the sustained release formulation of meloxicam.

Carprofen. Similar to results for meloxicam in mouse,¹⁰⁵ carprofen had no significant effect on CFA enhanced polyclonal antibody production in rabbit.⁶² Carprofen reduced inflammatory cell infiltrates, thrombus weight, vein wall thickness, and serum IL6 in a mouse model of venous thrombosis.⁸⁰ TNF α activity was reduced by carprofen in a rat subcutaneous pouch model of inflammation.¹⁰⁹ In a mouse model of traumatic brain injury, carprofen was shown to be neuroprotective and reduced brain levels of IL6 and IL1.²⁰⁸

Ketoprofen. Although several studies on the effects of ketoprofen on immune endpoints in rat have been reported, the use of this drug in rat is likely contraindicated due to its potential for gastrointestinal toxicity¹⁹⁴ and availability of other, less toxic options. In mice, ketoprofen has been shown to have profound effects on clinical endpoints, reducing cytokine release, and suppressing lymphocyte proportions of Th1 and Th17 cells in a collagen-induced arthritis model.³⁷ In several mouse models, ketoprofen has been shown to increase TNF α levels which appears to be an effect of the S-isomer of the drug.^{66,67,141,158} In pig, ketoprofen can inhibit LPS stimulated cytokine release in

vitro, although not in *vivo*, despite inhibiting PGE₂ under both conditions.²²⁴

Model Specific Effects of Analgesia

Rodents are commonly used for studies of immunology, inflammation, and infectious disease. A partial list includes vaccine development, antibody production, inflammation induced with CFA or carrageenan, and models of inflammatory bowel disease and arthritis. The majority, if not all, of these studies are completed in rodents without analgesics despite being associated with significant levels of pain. A limited number of infectious disease models have assessed the effects of analgesia on immune endpoints and disease severity or mortality. The following section will discuss the effects of analgesia on immune function and in specific models.

Vaccines and Monoclonal Antibody Production. The administration of vaccines is not generally associated with pain; however, the administration of infectious agents or neoplastic cells that the vaccines are targeting may be associated with significant pain. This is especially true with the recent focus on the use of vaccines and immunotherapies to treat various cancers. Unfortunately, very few studies have attempted to look at the effects of analgesics on vaccine efficacy (see Figure 2). Kolstad and colleagues demonstrated that acetaminophen, meloxicam, and buprenorphine decreased signs of pain in male C57BL/6J mice, but did not decrease the antibody response to immunization with antigen in either CFA or IFA.¹⁰⁸ However, in conflict with this, Filipczak and colleagues showed that the timing of administration and the type of opioid administered affects the cell- and humoral- mediate immune response in CBA mice, with oxycodone having the weakest immunomodulatory properties in mice.^{60,61} Another group, who recognized that analgesics are never withheld from cancer patients, specifically studied the effects of physiologically relevant doses of analgesics on an antitumor vaccine. This study found that morphine administered alone suppressed the antitumor effect of the antigen-specific DNA vaccine, but when coadministered with ketorolac, analgesia was provided to female C57BL/6 mice without compromising the antigen-specific immunity and antitumor effect of the naked DNA vaccine.²⁰³

While vaccines may not be painful, monoclonal antibody production can be associated with significant amounts of pain and distress.^{170,178} *In vivo* growth of hybridoma cells, resulting in accumulation of ascites fluid, has been reported to be a source of pain and distress, as has the injection of adjuvants and antibodies used to induce ascites.²⁰² The effects of morphine on antibody production has been evaluated in a number of studies, and results suggest that it may suppress antibody production in a strain, but not sex dependent manner.²⁸ More specifically, morphine consistently suppressed the primary antibody response in C3HeB/FeJ, C3H/HeJ, and C57BL/6 but not CxBk/ByJ or Balb/cByJ mice.²⁸ In addition, C57BL/6J bg^l/bg^l mice, which tend to be less sensitive than other strains to analgesic effects of morphine, were shown to have a decreased capacity to respond to antigenic challenge when implanted with morphine pellets.²⁹

In contrast to morphine, clinically relevant doses of meloxicam, buprenorphine, or a combination of both, did not affect antibody production in male BALB/c mice injected with pristane followed by hybridoma cells for antibody production, compared with saline controls.¹³⁶

Due to the variety of immunomodulatory effects seen in vaccine and antibody production studies, caution should be used with any analgesic agent. Partial μ -agonists (for example

Model	Species	Drug	Effect on Pain	Effect on Model	Reference
IFA/CFA immunization	Mouse	Acetaminophen (300 mg/kg PO, water)	↓ signs of pain	No effect	108
		Meloxicam (2 mg/kg SC SID)	↓ signs of pain	No effect	
		Buprenorphine (0.1 mg/kg SC BID)	↓ signs of pain	No effect	
Ascites/macrophage response	Mouse	Morphine (20 mg/kg IP BID)	No comment	↓ HI and CMI	61
		Fentanyl (10 mg/kg IP BID)	No comment	↓ HI and CMI	
		Methadone (30 mg/kg IP SID)	No comment	↓ HI and CMI	
Ascites/macrophage response	Mouse	Buprenorphine (2 mg/kg IP SID)	No comment	↓ CMI, ↑ HI	60
		Oxycodone (20 mg/kg IP BID)	No comment	↓ CMI, no effect on HI	
		Morphine (5 or 20 mg/kg/day IP)	Delayed tail flick	↓ CMI	
Vaccine challenge	Mouse			↑ tumor growth	203
		Ketorolac (2 or 5 mg/kg/day IP)	—	No effect	
		Morphine + Ketorolac	Delayed tail flick	Not tested	
Ascites	Mouse	Meloxicam (2 mg/kg SC SID)	No comment	No effect	136
		Buprenorphine (0.1 mg/kg SC BID)	No comment	No effect	
		Meloxicam + Buprenorphine	No comment	No effect	
Ascites	Mouse	Morphine (75 mg SC pellet)	No comment	↓ antibody production	28,29

Figure 2. Summary of vaccine and antibody production models in which analgesic effects were evaluated. HI – humeral immunity, CMI – cell mediated immunity, SID – once a day, BID – twice a day, PO – by mouth, SC – subcutaneous, IP – intraperitoneal

buprenorphine) or combinations of NSAID and partial μ -agonist can likely be used, but pilot studies may be necessary to identify any potential confounding effects of drug administration.

Inflammation models. Inflammation and associated pain is a primary component of many disease and injury conditions. Inflammatory pain can result from thermal, chemical, or mechanical injuries via nociceptors in the neural system. Mice and rats are used in a variety of different inflammation models that mimic the human condition, most commonly without any analgesia despite the knowledge that these conditions are associated with significant pain in humans. Figure 3 summarizes the effects that analgesics have been reported to have in models of inflammation.

Complete Freund Adjuvant and Carrageenan. An inflammatory state can be created by injecting chemical agents, such as CFA or carrageenan. Plantar intradermal injections of CFA have been used to study the effects of COX isoenzymes and is also a good model for studying novel analgesics for rheumatoid arthritis.¹⁵² Both ketorolac and celecoxib, administered intrathecally, transiently increased expression of inducible COX2 in the spinal cord of male Sprague–Dawley rats with adjuvant induced inflammation and relieved thermal hyperalgesia through blockade of COX.⁸⁸ In CFA-induced unilateral paw inflammation in a rodent model, μ and κ agonists decrease the severity of inflammation.²⁰¹ Similarly, carrageenan injection induces granuloma formation which has been used to evaluate general anti-inflammatory agents. Butorphanol decreased paw inflammation following carrageenan injections, with or without concurrent administration of indomethacin in Sprague–Dawley rats,²¹⁰ and acetaminophen reduced inflammatory hyperalgesia without affecting inflammation and central hyperalgesia in male Sprague–Dawley rats.²² It appears that both NSAID and opioids can have strong inflammation-modulating effects in these models and that their use is best avoided to avoid confounding analysis of the inflammatory response.

Rheumatoid Arthritis. Rheumatoid arthritis (RA) is a painful, chronic, autoimmune disease. Rodent models of rheumatoid arthritis are similarly painful, and significant refinement of these models to improve rodent welfare is necessary. NSAIDs are the mainstay therapy for pain relief in human RA patients, and opioids are rarely used. Although NSAID may provide appropriate analgesia for rodent subjects in models of RA, they can also markedly confound experimental results, by significantly modulating the inflammatory response and decreasing disease severity.^{2,54,75,91,228} Opioids have shown variable effects on model

endpoints that depend on the animal stock or strain used, type of opioid administered route of administration, and method of arthritis induction.^{50,71,213,215} A full discussion of the various effects of both NSAID and opioid analgesic agents can be found in the review by Peterson and colleagues.¹⁷¹ Because of the mixed response to conventional analgesics, pilot studies should be performed to evaluate the confounding effects of any analgesic and nonpharmacological measures are strongly recommended to enhance animal comfort and welfare.

Inflammatory Bowel Disease (IBD). IBD is a complex inflammatory disease that is generally considered to include both ulcerative colitis (UC) and Crohn disease (CD). Inflammatory lesions are generally limited to the large intestines and rectum in UC, but can occur in any part of the gastrointestinal tract in CD.¹⁷⁵ Regardless of the type of IBD, the condition is generally associated with significant abdominal pain, and requires management with an analgesic regimen in humans. Current work in mice shows that activation of the polymodal ion channel TRPV1 is also associated with chronic abdominal pain in the dextran sodium sulphate model (DSS) of ulcerative colitis.¹¹⁰ Unfortunately, translational rodent models frequently ignore the pain component of the disease process and analgesics are not commonly provided.

Many different methods are commonly employed to induce experimental inflammatory bowel disease. These are associated with acute and chronic intestinal inflammation and they all recapitulate different aspects of IBD.^{53,175,221,222} Pain is an essential feature of IBD and optimal treatment in animals can aid the translation to human medicine, where the challenge of intestinal pain is frequently met with opioids.^{24,31} This is because IBD is characterized by periods of remission and reactivation, and NSAID consumption is considered a primary cause of disease reactivation.^{57,106} Figure 4 summarizes the effects that analgesics have been reported to have in models of IBD.

In human medicine, it is not uncommon to also use non-traditional analgesic agents to manage the visceral pain associated with IBD.^{31,197} This includes: antidepressants, peppermint oil (antispasmodic), 5-HT₃ receptor antagonists, nonabsorbed antibiotics (such as, rifaximin), secretagogues, H₁-receptor antagonists, Neurokinin-2 receptor antagonists, and GABAergic agents.^{31,197} These agents remain largely untested in animals, but may provide alternative means of analgesia for the pain associated with experimental models of both UC and CD.

Model	Species	Drug	Effect on Pain	Effect on Model	Reference
CFA plantar injections	Rat	Celecoxib (20 or 100 ug IT once)	Delayed withdrawal	↑ spinal COX2 expression	88
Carrageenan plantar injections	Rat	Ketorolac (5 or 25 ug IT once)	Delayed withdrawal	↑ spinal COX2 expression	210
		Indomethacin (1, 2.5 or 5 mg/kg PO once)	No comment	Dose-dependent ↓ paw edema	
		Butorphanol (2 mg/kg SC once)	No comment	↓ paw edema	
Brewer's yeast plantar injections	Rat	Indomethacin + Butorphanol	No comment	↓ paw edema	22
		Acetaminophen (25, 50, 100 mg/kg PO once)	No significant effect on tail flick	↓ inflammation	
Adjuvant arthritis	Rat	Meloxicam (1.5 mg/kg PO SID)	No comment	↓ diamine oxidase activity ↑ myeloperoxidase activity GI ulceration	228
Adjuvant arthritis	Rat	Meloxicam (0.1 or 0.5 mg/kg PO SID)	No comment	↓ paw edema ↓ oxidative stress	2
Adjuvant arthritis	Rat	Meloxicam (0.06-0.5 mg/kg PO SID)	No comment	↓ paw swelling	54
				↓ bone and cartilage destruction	
		Piroxicam (0.15–1.35 mg/kg PO SID)	No comment	↓ paw swelling	
				↓ bone and cartilage destruction	
Collagen-induced arthritis	Mouse	Diclofenac (0.2–1.6 mg/kg PO SID)	No comment	↓ paw swelling	91
		Tenidap (3.1–25 mg/kg PO SID)	No comment	↓ paw swelling	
		Celecoxib (30 mg/kg PO BID)	No comment	↑ withdrawal latency (mechanical and thermal)	
Bacterial-induced arthritis	Rat	Buprenorphine (1 or 2 mg/kg PO BID)	Dose-dependent pain control	↓ paw swelling ↓ bone destruction	213
Adjuvant arthritis	Rat	Buprenorphine (0.01, 0.1 or 1 mg/kg SC SID)	No comment	↑ paw swelling ↑ joint destruction	71
Adjuvant arthritis	Rat	Morphine (SC, osmotic pump)	No comment	↑ paw swelling ↑ bone demineralization	50
				↑ bone erosion	
Adjuvant arthritis	Rat	Morphine (10 or 60 mg/kg/day SC)	No comment	↓ arthritic changes	215
		Buprenorphine (0.6 mg/kg/day PO)	No comment	No effect	

Figure 3. Summary of inflammation models in which analgesic effects were evaluated. IT – intrathecal, SID – once a day, BID – twice a day, PO – by mouth, SC – subcutaneous, IP - intraperitoneal

Model	Species	Drug	Effect on Pain	Effect on Model	Reference
DSS colitis	Mouse	Rofecoxib (2.5–10 mg/kg PO, water)	No comment	↓ inflammation	137
DSS colitis	Rat	Indomethacin (1 mg/kg PO SID)	No comment	↑ inflammation	161
		Celecoxib (3 mg/kg PO SID)	No comment		
DSS colitis	Mouse	Buprenorphine (0.05 mg/kg SC BID)	↓ signs of pain	↓ inflammation	24
		Tramadol (20 mg/kg SC SID)	↓ signs of pain	No effect	
Acetic acid colitis	Rat	Methadone (5 or 10 mg/kg SC SID)	No comment	↓ inflammation	55
TNBS	Rat	Meloxicam (3 mg/kg PO SID)	No comment	↓ inflammation	103
				Improved contractility	
		Diclofenac (10 mg/kg PO BID)	No comment	↑ colitis severity and mortality	
		Indomethacin (5 mg/kg PO BID)	No comment	↑ colitis severity and mortality	
TNBS	Mouse	Ketoprofen (10 mg/kg PO BID)	No comment	↑ colitis severity	24
		Celecoxib (15 mg/kg PO BID)	No comment	No effect	
		Buprenorphine (0.05 mg/kg SC BID)	↓ signs of pain	↓ inflammation, ↑ mortality	
TNBS	Mouse	Tramadol (20 mg/kg SC SID)	↓ signs of pain	No effect	229
		Buprenorphine analog (1 mg/kg IP once)	↓ signs of pain	↓ inflammation	

Figure 4. Summary of IBD models in which analgesic effects were evaluated. SID – once a day, BID – twice a day, PO – by mouth, SC – subcutaneous, IP - intraperitoneal

Ulcerative Colitis. Dextran sodium sulphate (DSS) causes a progressive chemical injury to the intestinal epithelium, resulting in exposure of the lamina propria and submucosal compartment to luminal antigens and enteric bacteria, thereby triggering inflammation.¹⁰⁰ The effectiveness of DSS-induced UC depends on several factors, including dosage (typically 1% to 5% DSS), duration (acute or chronic), manufacturer or batch of DSS, strain of animals (C3H/HeJ and BALB/c mice strains are more susceptible), sex of animals (male mice are more susceptible), and microbiota of animals (for example germ free compared with SPF).^{24,51,100,126,169} Several NSAID and opioids have been evaluated

in both mice and rats in the DSS model for their effects on the inflammatory process. Rofecoxib decreased inflammation in male BABL/c mice,¹³⁷ whereas indomethacin and celecoxib both worsened the severity of inflammation in both sexes of Wistar rats.^{161,195} Interestingly, although celecoxib administration exacerbated inflammation it protected from ulceration.¹⁹⁵ Buprenorphine was generally antiinflammatory in both BALB/c and CD1 mice, whereas tramadol did not affect inflammation, based on scoring of gut histology. Both treatment regimens appeared to provide adequate analgesia, and the authors recommend tramadol for future studies in either strain of mice.²⁴

Oxazolone causes a superficial inflammatory acute colitis that is limited to the distal colon.^{100, 126, 226} Animals demonstrate weight loss, diarrhea, ulcers, and loss of epithelial cells in the large intestines. Although rodents are anesthetized for intrarectal administration of Oxazolone, to the authors' knowledge, there have been no studies on the effects of analgesics, nor has analgesic use been documented in this model.^{100,126,226}

Acetic acid administration causes a chemical injury to the mucosal epithelium that induces a transient phenotype mimicking UC.^{53,126,131} The injury is characterized by ulceration of the distal colon and crypt abnormalities that begin to heal within days in mice and a few weeks in rats.^{53,126,131} Few studies have evaluated the effects of analgesics in this model. In one study, specifically looking at the gastroprotectant effects of opioids, methadone improved macroscopic and microscopic disease scores of colitis in male Wistar rats previously treated with acetic acid.⁵⁵

Crohn Disease. In the 2,4,6-Trinitrobenzene sulphonic acid (TNBS) model of Crohn disease, TNBS disrupts the epithelial layer of the colon and exposes the underlying lamina propria to bacterial components that lead to a severe transmural infiltrative colitis.¹⁰⁰ Colitis is associated with diarrhea, rectal prolapse, and weight loss. Several NSAID and opioids have been evaluated in both mice and rats in the TNBS model for their effects on the inflammatory process. Administration of rofecoxib reduced the colonic damage and inflammation in Wistar rats.¹³⁸ Administration of meloxicam to male Sprague–Dawley rats restored colonic contractility and decreased colonic inflammation.¹⁰³ Diclofenac, indomethacin, and ketoprofen all exacerbated colitis in male Wistar rats, but celecoxib had no significant effect.²⁶ In BALB/c mice, tramadol administration did not affect inflammation, but buprenorphine was antiinflammatory.²⁴ BU08070, a buprenorphine analog, produced a concentration-dependent decrease in inflammation and visceral pain-induced behaviors in male BALB/c mice.²²⁹

To keep murine models of UC and CD consistent with human treatments, opioids are generally recommended as therapeutics to decrease model associated discomfort and improve animal welfare. However, pilot studies are warranted to evaluate for potential confounding effects of opioid or NSAID analgesia in the specific model type and species. Based on the collective body of literature described herein, tramadol should be considered for IBD studies due to its clinical efficacy for relieving visceral pain and its lack of modulatory effects on inflammation.

Infectious Disease Models. Most extant studies on the effects of analgesics on immune function and disease in infectious disease models have used NSAID to explore the role of COX and prostaglandins in disease pathogenesis.^{113,144,145,156,196,218} The one notable exception is a study on the effect of buprenorphine in a mouse model of intracranial lymphocytic choriomeningitis virus (LCMV) infection.¹⁵⁵ Intracranial LCMV in mouse is used to model CTL-mediated meningitis, and produces characteristic fatal meningitis 6 to 8 d post infection, which may be associated with significant pain and distress.⁹⁹ Mice intracranially infected with LCMV and treated with buprenorphine (0.05 mg/kg s.c.) followed by osmotic pump delivery (0.15 mg/kg/day) for 1 wk, had markedly reduced pain scores and no clinical signs of pain.¹⁵⁵ Buprenorphine treatment had no effect on LCMV-induced CTL responses or LCMV induced brain infiltration by lymphocytes and virus specific CTLs.¹⁵⁵

Conclusion

The balance between appropriate analgesic use for animal welfare, and analgesic impact on experimental results continues to present significant challenges to the research community.¹⁷¹ Furthermore, relatively little is currently known about the role

of gender in the interaction between analgesics and immune function. However, gender has a major influence on both the prevalence and severity of pain and sex related differences in neuroimmune interactions (in particular glial cell function) appears to underpin this phenomenon.^{49,96,134} Thus in light of NIH directives, better understanding of gender-related differences in the effects of pain and analgesia on neuroimmune function in preclinical studies is critically important. In human medicine, archaic concepts such as “pain medication may mask clinical signs” and “nobody ever died from pain” have been refuted by years of research and clinical experience. It would be unethical and malpractice to withhold analgesics from human patients experiencing pain from cancer, autoimmune disease, infection or the innumerable other diseases which cause pain. In this context, the possibility should be considered that in some instances the translatability of animal models may be improved if analgesics are administered, not withheld, and used in a manner that more closely matches human treatment.^{39,90} What is clear from this review is that many questions remain regarding the impact of analgesics on immune function and that there is no one drug that represents the “Magic Bullet” analgesic for all models. In many cases, the literature is incomplete, or does not exist, necessitating empirical choices or pilot studies to evaluate or optimize the use of analgesics for *in vivo* studies of immunology and inflammation. Responsibility for appropriate analgesic drug use in the absence of published data lies with the investigator, and is shared with laboratory animal veterinarians and IACUC members. Our hope is that research and development of new analgesic drugs and regimens will progress and help improve our ability to appropriately manage pain and minimally impact experimental results

References

1. Agarwal N, Pacher P, Tegeder I, Amaya F, Constantin CE, Brenner GJ, Rubino T, Michalski CW, Marsicano G, Monory K, Mackie K, Marian C, Batkai S, Parolaro D, Fischer MJ, Reeh P, Kunos G, Kress M, Lutz B, Woolf CJ, Kuner R. 2007. Cannabinoids mediate analgesia largely via peripheral type 1 cannabinoid receptors in nociceptors. *Nat Neurosci* 10:870–879. <https://doi.org/10.1038/nn1916>.
2. Agha AM, El-Khatib AS, Al-Zuhair H. 1999. Modulation of oxidant status by meloxicam in experimentally induced arthritis. *Pharmacol Res* 40:385–392. <https://doi.org/10.1006/phrs.1999.0522>.
3. Ahlers O, Nachtigall I, Lenze J, Goldmann A, Schulte E, Höhne C, Fritz G, Keh D. 2008. Intraoperative thoracic epidural anaesthesia attenuates stress-induced immunosuppression in patients undergoing major abdominal surgery. *Br J Anaesth* 101:781–787. <https://doi.org/10.1093/bja/aen287>.
4. Ahn K, McKinney MK, Cravatt BF. 2008. Enzymatic pathways that regulate endocannabinoid signaling in the nervous system. *Chem Rev* 108:1687–1707. <https://doi.org/10.1021/cr0782067>.
5. Al-Hashimi M, Scott SWM, Thompson JP, Lambert DG. 2013. Opioids and immune modulation: more questions than answers. *Br J Anaesth* 111:80–88. <https://doi.org/10.1093/bja/aet153>.
6. Allen A, Kendall LV. 2018. Measuring immune system perturbations associated with the use of buprenorphine in laboratory mice. Abstracts presented at the AALAS 69th National Meeting, Baltimore, Maryland, October 28–01 November 2018. *J Am Assoc Lab Anim Sci* 57:609.
7. Allendorf JD, Bessler M, Horvath KD, Marvin MR, Laird DA, Whelan RL. 1999. Increased tumor establishment and growth after open vs laparoscopic surgery in mice may be related to differences in postoperative T-cell function. *Surg Endosc* 13:233–235. <https://doi.org/10.1007/s004649900952>.
8. Amir R, Argoff CE, Bennett GJ, Cummins TR, Durieux ME, Gerner P, Gold MS, Porreca F, Strichartz GR. 2006. The role of

- sodium channels in chronic inflammatory and neuropathic pain. *J Pain* 7:S1–S29. <https://doi.org/10.1016/j.jpain.2006.01.444>.
9. **Amodeo G, Bugada D, Franchi S, Moschetti G, Grimaldi S, Panerai A, Allegri M, Sacerdote P.** 2018. Immune function after major surgical interventions: the effect of postoperative pain treatment. *J Pain Res* 11:1297–1305. <https://doi.org/10.2147/JPR.S158230>.
10. **Ando T, Ogawa J, Fujiwara H, Yokotachi S, Maeda K, Kohiruimaki M, Ohtsuka H, Watanabe D.** 2009. Effect of lidocaine hydrochloride on the function of bovine peripheral leukocytes. *J Vet Med Sci* 71:387–390. <https://doi.org/10.1292/jvms.71.387>.
11. **Axiak-Bechtel SM, Tsuruta K, Amorim J, Donaldson R, Lino G, Honaker A, Monibi F, Dodam J, DeClue A.** 2015. Effects of tramadol and o-desmethylnaloxone on canine innate immune system function. *Vet Anaesth Analg* 42:260–268. <https://doi.org/10.1111/vaa.12201>.
12. **Azuma Y, Ohura K.** 2004. Immunological modulation by lidocaine-epinephrine and prilocaine-felypressin on the functions related to natural immunity in neutrophils and macrophages. *Curr Drug Targets Immune Endocr Metabol Disord* 4:29–36. <https://doi.org/10.2174/1568008043339974>.
13. **Azuma Y, Shinohara M, Wang PL, Suese Y, Yasuda H, Ohura K.** 2000. Comparison of inhibitory effects of local anesthetics on immune functions of neutrophils. *Int J Immunopharmacol* 22:789–796. [https://doi.org/10.1016/S0192-0561\(00\)00040-0](https://doi.org/10.1016/S0192-0561(00)00040-0).
14. **Bar-Yosef S, Melamed R, Page GG, Shakhar G, Shakhar K, Ben-Eliyahu S.** 2001. Attenuation of the tumor-promoting effect of surgery by spinal blockade in rats. *Anesthesiology* 94:1066–1073. <https://doi.org/10.1097/0000542-200106000-00022>.
15. **Baral P, Udit S, Chiu IM.** 2019. Pain and immunity: implications for host defence. *Nat Rev Immunol* 19:433–447. <https://doi.org/10.1038/s41577-019-0147-2>.
16. **Beggs S, Liu XJ, Kwan C, Salter MW.** 2010. Peripheral nerve injury and TRPV1-expressing primary afferent C-fibers cause opening of the blood-brain barrier. *Mol Pain* 6:1–12. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2984489/pdf/1744-8069-6-74.pdf>.
17. **Beilin B, Bessler H, Mayburd E, Smirnov G, Dekel A, Yardeni I, Shavit Y.** 2003. Effects of preemptive analgesia on pain and cytokine production in the postoperative period. *Anesthesiology* 98:151–155. <https://doi.org/10.1097/0000542-200301000-00024>.
18. **Beilin B, Shavit Y, Trabek E, Mordashev B, Mayburd E, Zeidel A, Bessler H.** 2003. The effects of postoperative pain management on immune response to surgery. *Anesth Analg* 97:822–827. <https://doi.org/10.1213/01.ANE.0000078586.82810.3B>.
19. **Ben-Eliyahu S, Page GG, Yirmiya R, Shakhar G.** 1999. Evidence that stress and surgical interventions promote tumor development by suppressing natural killer cell activity. *Int J Cancer* 80:880–888. [https://doi.org/10.1002/\(SICI\)1097-0215\(19990315\)80:6<880::AID-IJC14>3.0.CO;2-Y](https://doi.org/10.1002/(SICI)1097-0215(19990315)80:6<880::AID-IJC14>3.0.CO;2-Y).
20. **Benito C, Kim WK, Chavarria I, Hillard CJ, Mackie K, Tolon RM, Williams K, Romero J.** 2005. A glial endogenous cannabinoid system is upregulated in the brains of macaques with simian immunodeficiency virus-induced encephalitis. *J Neurosci* 25:2530–2536. <https://doi.org/10.1523/JNEUROSCI.3923-04.2005>.
21. **Benito C, Tolón RM, Pazos MR, Núñez E, Castillo AI, Romero J.** 2008. Cannabinoid CB2 receptors in human brain inflammation. *Br J Pharmacol* 153:277–285. <https://doi.org/10.1038/sj.bjp.0707505>.
22. **Bianchi M, Panerai AE.** 1996. The dose-related effects of paracetamol on hyperalgesia and nociception in the rat. *Br J Pharmacol* 117:130–132. <https://doi.org/10.1111/j.1476-5381.1996.tb15164.x>.
23. **Bianchi M, Rossoni G, Sacerdote P, Panerai AE.** 1999. Effects of tramadol on experimental inflammation. *Fundam Clin Pharmacol* 13:220–225. <https://doi.org/10.1111/j.1472-8206.1999.tb00342.x>.
24. **Blennerhassett MG, Lourenssen SR, Parlow LRG, Ghasemlou N, Winterborn AN.** 2017. Analgesia and mouse strain influence neuromuscular plasticity in inflamed intestine. *Neurogastroenterol Motil* 29:1–12. <https://doi.org/10.1111/nmo.13097>.
25. **Börner C, Lanciotti S, Koch T, Holtt V, Kraus J.** 2013. μ opioid receptor agonist-selective regulation of interleukin-4 in T lymphocytes. *J Neuroimmunol* 263:35–42. <https://doi.org/10.1016/j.jneuroim.2013.07.012>.
26. **Breganó JW, Barbosa DS, El Kadri MZ, Rodrigues MA, Cecchini R, Dichi I.** 2014. Comparison of selective and non selective cyclooxygenase 2 inhibitors in experimental colitis exacerbation: role of leukotriene B4 and superoxide dismutase. *Arq Gastroenterol* 51:226–234. <https://doi.org/10.1590/S0004-28032014000300012>.
27. **Bryant CE, Farnfield BA, Janicke HJ.** 2003. Evaluation of the ability of carprofen and flunixin meglumine to inhibit activation of nuclear factor κ B. *Am J Vet Res* 64:211–215. <https://doi.org/10.2460/ajvr.2003.64.211>.
28. **Bussiere JL, Adler MW, Rogers TJ, Eisenstein TK.** 1992. Differential effects of morphine and naltrexone on the antibody response in various mouse strains. *Immunopharmacol Immunotoxicol* 14:657–673. <https://doi.org/10.3109/08923979209005416>.
29. **Bussiere JL, Adler MW, Rogers TJ, Eisenstein TK.** 1993. Effects of in vivo morphine treatment on antibody responses in C57BL/6 bgJ/bgJ (beige) mice. *Life Sci* 52:PL43–PL48. [https://doi.org/10.1016/0024-3205\(93\)90157-X](https://doi.org/10.1016/0024-3205(93)90157-X).
30. **Cabral GA, Griffin-Thomas L.** 2009. Emerging role of the cannabinoid receptor CB2 in immune regulation: therapeutic prospects for neuroinflammation. *Expert Rev Mol Med* 11:1–31. <https://doi.org/10.1017/S1462399409000957>.
31. **Camilleri M, Boeckstaens G.** 2017. Dietary and pharmacological treatment of abdominal pain in IBS. *Gut* 66:966–974. <https://doi.org/10.1136/gutjnl-2016-313425>.
32. **Carrier EJ, Kearn CS, Barkmeier AJ, Breese NM, Yang W, Nithipatikom K, Pfister SL, Campbell WB, Hillard CJ.** 2004. Cultured rat microglial cells synthesize the endocannabinoid 2-arachidonylglycerol, which increases proliferation via a CB2 receptor-dependent mechanism. *Mol Pharmacol* 65:999–1007. <https://doi.org/10.1124/mol.65.4.999>.
33. **Carrigan KA, Saurer TB, James SG, Lysle DT.** 2004. Buprenorphine produces naltrexone reversible alterations of immune status. *Int Immunopharmacol* 4:419–428. <https://doi.org/10.1016/j.intimp.2004.01.011>.
34. **Chen Q, Luo Y, Kuang S, Yang Y, Tian X, Ma J, Mai S, Xue L, Yang J.** 2017. Cyclooxygenase-2 signalling pathway in the cortex is involved in the pathophysiological mechanisms in the rat model of depression. *Sci Rep* 7:1–12. <https://doi.org/10.1038/s41598-017-00609-7>.
35. **Chiu IM, Heesters BA, Ghasemlou N, Von Hehn CA, Zhao F, Tran J, Wainger B, Strominger A, Muralidharan S, Horswill AR, Bubeck Wardenburg J, Hwang SW, Carroll MC, Woolf CJ.** 2013. Bacteria activate sensory neurons that modulate pain and inflammation. *Nature* 501:52–57. <https://doi.org/10.1038/nature12479>.
36. **Chiu IM, von Hehn CA, Woolf CJ.** 2012. Neurogenic inflammation and the peripheral nervous system in host defense and immunopathology. *Nat Neurosci* 15:1063–1067. <https://doi.org/10.1038/nn.3144>.
37. **Choi JK, Kim SW, Kim DS, Lee JY, Lee S, Oh HM, Ha YS, Yoo J, Park PH, Shin TY, Kwon TK, Rho MC, Kim SH.** 2016. Oleic acid acetate inhibits rheumatoid arthritis by modulating T cell immune responses and matrix-degrading enzymes. *Toxicol Appl Pharmacol* 290:1–9. <https://doi.org/10.1016/j.taap.2015.11.005>.
38. **Clark JD, Shi X, Li X, Qiao Y, Liang D, Angst MS, Yeomans DC.** 2007. Morphine reduces local cytokine expression and neutrophil infiltration after incision. *Mol Pain* 3:1–12. <https://doi.org/10.1186/1744-8069-3-28>.
39. **Clutton RE.** 2018. A review of factors affecting analgesic selection in large animals undergoing translational research. *Vet J* 236:12–22. <https://doi.org/10.1016/j.tvjl.2018.04.006>.
40. **Concannon RM, Okine BN, Finn DP, Dowd E.** 2015. Differential upregulation of the cannabinoid CB₂ receptor in neurotoxic and inflammation-driven rat models of Parkinson's disease. *Exp Neurol* 269:133–141. <https://doi.org/10.1016/j.expneurol.2015.04.007>.
41. **Concannon RM, Okine BN, Finn DP, Dowd E.** 2016. Upregulation of the cannabinoid CB2 receptor in environmental and viral inflammation-driven rat models of Parkinson's disease. *Exp Neurol* 283:204–212. <https://doi.org/10.1016/j.expneurol.2016.06.014>.
42. **Craner MJ, Damarjian TG, Liu S, Hains BC, Lo AC, Black JA, Newcombe J, Cuzner ML, Waxman SG.** 2005. Sodium channels contribute to microglia/macrophage activation and function in EAE and MS. *Glia* 49:220–229. <https://doi.org/10.1002/glia.20112>.

43. D'Mello R, Dickenson AH. 2008. Spinal cord mechanisms of pain. *Br J Anaesth* 101:8–16. <https://doi.org/10.1093/bja/aen088>.
44. Dąbrowska AM, Słotwiński R. 2014. The immune response to surgery and infection. *Cent Eur J Immunol* 39:532–537. <https://doi.org/10.5114/ceji.2014.47741>.
45. Di S, Boudaba C, Popescu IR, Weng FJ, Harris C, Marcheselli VL, Bazan NG, Tasker JG. 2005. Activity-dependent release and actions of endocannabinoids in the rat hypothalamic supraoptic nucleus. *J Physiol* 569:751–760. <https://doi.org/10.1113/jphysiol.2005.097477>.
46. Díaz-González F, Gonzalez-Alvaro I, Campanero MR, Mollinedo F, del Pozo MA, Munoz C, Pivel JP, Sanchez-Madrid F. 1995. Prevention of in vitro neutrophil-endothelial attachment through shedding of L-selectin by nonsteroidal antiinflammatory drugs. *J Clin Invest* 95:1756–1765. <https://doi.org/10.1172/JCI117853>.
47. Díaz-González F, Sánchez-Madrid F. 2015. NSAIDs: learning new tricks from old drugs. *Eur J Immunol* 45:679–686. <https://doi.org/10.1002/eji.201445222>.
48. Dik B, Coskun D, Bahcivan E, Er A. 2019. Doxycycline and meloxicam can treat neuroinflammation by increasing activity of antioxidant enzymes in rat brain. *Pak J Pharm Sci* 32:391–396.
49. Dodds KN, Beckett EA, Evans SF, Grace PM, Watkins LR, Hutchinson MR. 2016. Glial contributions to visceral pain: implications for disease etiology and the female predominance of persistent pain. *Transl Psychiatry* 6:1–13. <https://doi.org/10.1038/tp.2016.168>.
50. Earl JR, Claxson AW, Blake DR, Morris CJ. 1994. Proinflammatory effects of morphine in the rat adjuvant arthritis model. *Int J Tissue React* 16:163–170.
51. Eichele DD, Kharbanda KK. 2017. Dextran sodium sulfate colitis murine model: An indispensable tool for advancing our understanding of inflammatory bowel diseases pathogenesis. *World J Gastroenterol* 23:6016–6029. <https://doi.org/10.3748/wjg.v23.i33.6016>.
52. Eljaschewitsch E, Witting A, Mawrin C, Lee T, Schmidt PM, Wolf S, Hoertnagl H, Raine CS, Schneider-Stock R, Nitsch R, Ullrich O. 2006. The endocannabinoid anandamide protects neurons during CNS inflammation by induction of MKP-1 in microglial cells. *Neuron* 49:67–79. <https://doi.org/10.1016/j.neuron.2005.11.027>.
53. Elson CO, Sartor RB, Tennyson GS, Riddell RH. 1995. Experimental models of inflammatory bowel disease. *Gastroenterology* 109:1344–1367. [https://doi.org/10.1016/0016-5085\(95\)90599-5](https://doi.org/10.1016/0016-5085(95)90599-5).
54. Engelhardt G, Homma D, Schnitzler C. 1995. Meloxicam: a potent inhibitor of adjuvant arthritis in the Lewis rat. *Inflamm Res* 44:548–555. <https://doi.org/10.1007/BF01757360>.
55. Fakhraei N, Javadian N, Rahimian R, Nili F, Rahimi N, Hashemizadeh S, Dehpour AR. 2018. Involvement of central opioid receptors in protective effects of methadone on experimental colitis in rats. *Inflammopharmacology* 26:1399–1413. <https://doi.org/10.1007/s10787-018-0538-1>.
56. Favia AD, Habrant D, Scarpelli R, Migliore M, Albani C, Bertozzi SM, Dionisi M, Tarozzo G, Piomelli D, Cavalli A, De Vivo M. 2012. Identification and characterization of carprofen as a multi-target fatty acid amide hydrolase/cyclooxygenase inhibitor. *J Med Chem* 55:8807–8826. <https://doi.org/10.1021/jm3011146>.
57. Feagins LA, Cryer BL. 2010. Do nonsteroidal antiinflammatory drugs cause exacerbations of inflammatory bowel disease? *Dig Dis Sci* 55:226–232. <https://doi.org/10.1007/s10620-009-1042-7>.
58. Ferrante CJ, Leibovich SJ. 2012. Regulation of macrophage polarization and wound healing. *Adv Wound Care (New Rochelle)* 1:10–16. <https://doi.org/10.1089/wound.2011.0307>.
59. Ferraz CC, Henry MA, Hargreaves KM, Diogenes A. 2011. Lipopolysaccharide from *Porphyrromonas gingivalis* sensitizes capsaicin-sensitive nociceptors. *J Endod* 37:45–48. <https://doi.org/10.1016/j.joen.2007.07.001>.
60. Filipczak-Bryniarska I, Nazimek K, Nowak B, Kozłowski M, Wąsik M, Bryniarski K. 2018. In contrast to morphine, buprenorphine enhances macrophage-induced humoral immunity and, as oxycodone, slightly suppresses the effector phase of cell-mediated immune response in mice. *Int Immunopharmacol* 54:344–353. <https://doi.org/10.1016/j.intimp.2017.11.039>.
61. Filipczak-Bryniarska I, Nowak B, Sikora E, Nazimek K, Woron J, Wordliczek J, Bryniarski K. 2012. The influence of opioids on the humoral and cell-mediated immune responses in mice. The role of macrophages. *Pharmacol Rep* 64:1200–1215. [https://doi.org/10.1016/S1734-1140\(12\)70916-7](https://doi.org/10.1016/S1734-1140(12)70916-7).
62. Fishback JE, Stronsky SM, Green CA, Bean KD, Froude JW. 2016. Antibody production in rabbits administered Freund's complete adjuvant and carprofen concurrently. *Lab Anim (NY)* 45:63–66. <https://doi.org/10.1038/labanim.937>. Erratum: Antibody production in rabbits administered Freund's complete adjuvant and carprofen concurrently. *Lab Anim NY*. 2016.
63. Fleshner M, Bellgrau D, Watkins LR, Laudenslager ML, Maier SF. 1995. Stress-induced reduction in the rat mixed lymphocyte reaction is due to macrophages and not to changes in T cell phenotypes. *J Neuroimmunol* 56:45–52. [https://doi.org/10.1016/0165-5728\(94\)00132-8](https://doi.org/10.1016/0165-5728(94)00132-8).
64. Franchi S, Panerai AE, Sacerdote P. 2007. Buprenorphine ameliorates the effect of surgery on hypothalamus-pituitary-adrenal axis, natural killer cell activity and metastatic colonization in rats in comparison with morphine or fentanyl treatment. *Brain Behav Immun* 21:767–774. <https://doi.org/10.1016/j.bbi.2007.01.001>.
65. Fujino K, Takami Y, de la Fuente SG, Ludwig KA, Mantyh CR. 2004. Inhibition of the vanilloid receptor subtype-1 attenuates TNBS-colitis. *J Gastrointest Surg* 8:842–847, discussion 847–848. <https://doi.org/10.1016/j.gassur.2004.07.011>.
66. Ghezzi P, Melillo G, Meazza C, Sacco S, Pellegrini L, Asti C, Porzio S, Marullo A, Sabbatini V, Caselli G, Bertini R. 1998. Differential contribution of R and S isomers in ketoprofen anti-inflammatory activity: role of cytokine modulation. *J Pharmacol Exp Ther* 287:969–974.
67. Ghezzi P, Sacco S, Agnello D, Marullo A, Caselli G, Bertini R. 2000. Lps induces IL6 in the brain and in serum largely through TNF production. *Cytokine* 12:1205–1210. <https://doi.org/10.1006/cyto.2000.0697>.
68. Gomez-Flores R, Weber RJ. 2000. Differential effects of buprenorphine and morphine on immune and neuroendocrine functions following acute administration in the rat mesencephalon periaqueductal gray. *Immunopharmacology* 48:145–156. [https://doi.org/10.1016/S0162-3109\(00\)00198-3](https://doi.org/10.1016/S0162-3109(00)00198-3).
69. Grace PM, Hutchinson MR, Maier SF, Watkins LR. 2014. Pathological pain and the neuroimmune interface. *Nat Rev Immunol* 14:217–231. <https://doi.org/10.1038/nri3621>.
70. Gray A, Marrero-Berrios I, Weinberg J, Manchikalapati D, SchianodiCola J, Schloss RS, Yarmush J. 2016. The effect of local anesthetic on proinflammatory macrophage modulation by mesenchymal stromal cells. *Int Immunopharmacol* 33:48–54. <https://doi.org/10.1016/j.intimp.2016.01.019>.
71. Hall TJ, Jagher B, Schaeublin M, Wiesenberg I. 1996. The analgesic drug buprenorphine inhibits osteoclastic bone resorption in vitro, but is proinflammatory in rat adjuvant arthritis. *Inflamm Res* 45:299–302. <https://doi.org/10.1007/BF02280995>.
72. Hanke ML, Kielian T. 2011. Toll-like receptors in health and disease in the brain: mechanisms and therapeutic potential. *Clin Sci (Lond)* 121:367–387. <https://doi.org/10.1042/CS20110164>.
73. Hanson CE, Ruble GR, Essiet I, Hartman AB. 2001. Effects of buprenorphine on immunogenicity and protective efficacy in the guinea pig keratoconjunctivitis model (Sereny test). *Comp Med* 51:224–229.
74. Hasegawa A, Iwasaka H, Hagiwara S, Hasegawa R, Kudo K, Kusaka J, Asai N, Noguchi T. 2011. Remifentanyl and glucose suppress inflammation in a rat model of surgical stress. *Surg Today* 41:1617–1621. <https://doi.org/10.1007/s00595-010-4457-z>.
75. Hawkins P, Armstrong R, Boden T, Garside P, Knight K, Lilley E, Seed M, Wilkinson M, Williams RO. 2015. Applying refinement to the use of mice and rats in rheumatoid arthritis research. *Inflammopharmacology* 23:131–150. <https://doi.org/10.1007/s10787-015-0241-4>.
76. Helley MP, Abate W, Jackson SK, Bennett JH, Thompson SW. 2015. The expression of Toll-like receptor 4, 7 and co-receptors in neurochemical sub-populations of rat trigeminal ganglion sensory neurons. *Neuroscience* 310:686–698. <https://doi.org/10.1016/j.neuroscience.2015.09.069>.

77. Hensler T, Hecker H, Heeg K, Heidecke CD, Bartels H, Barthlen W, Wagner H, Siewert JR, Holzmann B. 1997. Distinct mechanisms of immunosuppression as a consequence of major surgery. *Infect Immun* **65**:2283–2291.
78. Herndon NL, Bandyopadhyay S, Hod EA, Prestia KA. 2016. Sustained-release buprenorphine improves postsurgical clinical condition but does not alter survival or cytokine levels in a murine model of polymicrobial sepsis. *Comp Med* **66**:455–462.
79. Herrera-García A, Domínguez-Luis M, Arce-Franco M, López-Fernández J, Fera M, Barreiro O, Sánchez-Madrid F, Díaz-González F. 2013. In vivo modulation of the inflammatory response by nonsteroidal antiinflammatory drug-related compounds that trigger L-selectin shedding. *Eur J Immunol* **43**:55–64. <https://doi.org/10.1002/eji.201242805>.
80. Hish GA Jr, Diaz JA, Hawley AE, Myers DD Jr, Lester PA. 2014. Effects of analgesic use on inflammation and hematology in a murine model of venous thrombosis. *J Am Assoc Lab Anim Sci* **53**:485–493.
81. Hogan BV, Peter MB, Shenoy HG, Horgan K, Hughes TA. 2011. Surgery induced immunosuppression. *Surgeon* **9**:38–43. <https://doi.org/10.1016/j.surge.2010.07.011>
82. Hohmann AG. 2002. Spinal and peripheral mechanisms of cannabinoid antinociception: behavioral, neurophysiological and neuroanatomical perspectives. *Chem Phys Lipids* **121**:173–190. [https://doi.org/10.1016/S0009-3084\(02\)00154-8](https://doi.org/10.1016/S0009-3084(02)00154-8).
83. Hohmann AG, Herkenham M. 1999. Localization of central cannabinoid CB1 receptor messenger RNA in neuronal subpopulations of rat dorsal root ganglia: a double-label in situ hybridization study. *Neuroscience* **90**:923–931. [https://doi.org/10.1016/S0306-4522\(98\)00524-7](https://doi.org/10.1016/S0306-4522(98)00524-7).
84. Hollmann MW, Durieux ME. 2000. Local anesthetics and the inflammatory response: a new therapeutic indication? *Anesthesiology* **93**:858–875. <https://doi.org/10.1097/0000542-200009000-00038>.
85. Horváth A, Tékus V, Bencze N, Szentes N, Scheich B, Bölskei K, Szőke É, Mócsai A, Tóth-Sarudy É, Mátyus P, Pintér E, Helyes Z. 2018. Analgesic effects of the novel semicarbazide-sensitive amine oxidase inhibitor SZV 1287 in mouse pain models with neuropathic mechanisms: Involvement of transient receptor potential vanilloid 1 and ankyrin 1 receptors. *Pharmacol Res* **131**:231–243. <https://doi.org/10.1016/j.phrs.2018.02.006>.
86. Horváth G, Kemény Á, Barthó L, Molnár P, Deli J, Szente L, Bozo T, Pál S, Sándor K, Szőke E, Szolcsanyi J, Helyes Z. 2015. Effects of some natural carotenoids on TRPA1- and TRPV1-induced neurogenic inflammatory processes in vivo in the mouse skin. *J Mol Neurosci* **56**:113–121. <https://doi.org/10.1007/s12031-014-0472-7>.
87. Hsing CH, Wang JJ. 2015. Clinical implication of perioperative inflammatory cytokine alteration. *Acta Anaesthesiol Taiwan* **53**:23–28. <https://doi.org/10.1016/j.aat.2015.03.002>.
88. Hsueh SF, Lu CY, Chao CS, Tan PH, Huang YW, Hsieh SW, Hsiao HT, Chung NC, Lin SH, Huang PL, Lyu PC, Yang LC. 2004. Nonsteroidal antiinflammatory drugs increase expression of inducible COX2 isoform of cyclooxygenase in spinal cord of rats with adjuvant induced inflammation. *Brain Res Mol Brain Res* **125**:113–119. <https://doi.org/10.1016/j.molbrainres.2004.03.016>.
89. Hu YF, Guo Y, Cheng GF. 2001. [[Inhibitory effects of indomethacin and meloxicam on NF-kappa B in mouse peritoneal macrophages]] Yao Xue Bao **36**:161–164. [Article in Chinese].
90. Hummel M, Whiteside GT. 2017. Measuring and realizing the translational significance of preclinical in vivo studies of painful osteoarthritis. *Osteoarthritis Cartilage* **25**:376–384. <https://doi.org/10.1016/j.joca.2016.08.007>.
91. Inglis JJ, Notley CA, Essex D, Wilson AW, Feldmann M, Anand P, Williams R. 2007. Collagen-induced arthritis as a model of hyperalgesia: functional and cellular analysis of the analgesic actions of tumor necrosis factor blockade. *Arthritis Rheum* **56**:4015–4023. <https://doi.org/10.1002/art.23063>.
92. Iwanaka T, Arkovitz MS, Arya G, Ziegler MM. 1997. Evaluation of operative stress and peritoneal macrophage function in minimally invasive operations. *J Am Coll Surg* **184**:357–363.
93. Jarrar YB, Jarrar Q, Abed A, Abu-Shalhoob M. 2019. Effects of nonsteroidal anti-inflammatory drugs on the expression of arachidonic acid-metabolizing Cyp450 genes in mouse hearts, kidneys and livers. *Prostaglandins Other Lipid Mediat* **141**:14–21. <https://doi.org/10.1016/j.prostaglandins.2019.02.003>.
94. Jeon YT, Na H, Ryu H, Chung Y. 2015. Modulation of dendritic cell activation and subsequent Th1 cell polarization by lidocaine. *PLoS One* **10**:1–17. <https://doi.org/10.1371/journal.pone.0139845>.
95. Ji RR, Chamesian A, Zhang YQ. 2016. Pain regulation by non-neuronal cells and inflammation. *Science* **354**:572–577. <https://doi.org/10.1126/science.aaf8924>.
96. Ji RR, Nackley A, Huh Y, Terrando N, Maixner W. 2018. Neuroinflammation and central sensitization in chronic and widespread pain. *Anesthesiology* **129**:343–366. <https://doi.org/10.1097/ALN.0000000000002130>.
97. Joshi GP, Ogunnaike BO. 2005. Consequences of inadequate postoperative pain relief and chronic persistent postoperative pain. *Anesthesiol Clin North America* **23**:21–36. <https://doi.org/10.1016/j.atc.2004.11.013>.
98. Kang SC, Matsutani T, Choudhry MA, Schwacha MG, Rue LW, Bland KI, Chaudry IH. 2004. Are the immune responses different in middle-aged and young mice following bone fracture, tissue trauma and hemorrhage? *Cytokine* **26**:223–230. <https://doi.org/10.1016/j.cyto.2004.03.005>.
99. Kang SS, McGavern DB. 2008. Lymphocytic choriomeningitis infection of the central nervous system. *Front Biosci* **13**:4529–4543. <https://doi.org/10.2741/3021>
100. Kawada M, Arihiro A, Mizoguchi E. 2007. Insights from advances in research of chemically induced experimental models of human inflammatory bowel disease. *World J Gastroenterol* **13**:5581–5593. <https://doi.org/10.3748/wjg.v13.i42.5581>.
101. Kawasaki T, Kawasaki C, Sata T, Chaudry IH. 2011. Lidocaine suppresses mouse Peyer's Patch T cell functions and induces bacterial translocation. *Surgery* **149**:106–113. <https://doi.org/10.1016/j.surg.2010.03.024>.
102. Kelly S, Donaldson LF. 2008. Peripheral cannabinoid CB1 receptors inhibit evoked responses of nociceptive neurones in vivo. *Eur J Pharmacol* **586**:160–163. <https://doi.org/10.1016/j.ejphar.2008.03.003>.
103. Khan I, Oriowo MA. 2006. Mechanism underlying the reversal of contractility dysfunction in experimental colitis by cyclooxygenase-2 inhibition. *Inflammopharmacology* **14**:28–35. <https://doi.org/10.1007/s10787-006-1507-7>.
104. Kihara N, de la Fuente SG, Fujino K, Takahashi T, Pappas TN, Mantyh CR. 2003. Vanilloid receptor-1 containing primary sensory neurones mediate dextran sulphate sodium induced colitis in rats. *Gut* **52**:713–719. <https://doi.org/10.1136/gut.52.5.713>.
105. Kimura F, Shimizu H, Yoshidome H, Ohtsuka M, Miyazaki M. 2010. Immunosuppression following surgical and traumatic injury. *Surg Today* **40**:793–808. <https://doi.org/10.1007/s00595-010-4323-z>.
106. Klein A, Eliakim R. 2010. Non steroidal antiinflammatory drugs and inflammatory bowel disease. *Pharmaceuticals (Basel)* **3**:1084–1092. <https://doi.org/10.3390/ph3041084>.
107. Koksoy S, Sahin Z, Karsli B. 2013. Comparison of the effects of desflurane and bupivacaine on Th1 and Th2 responses. *Clin Lab* **59**:1215–1220. <https://doi.org/10.7754/Clin.Lab.2013.120413>.
108. Kolstad AM, Rodriguiz RM, Kim CJ, Hale LP. 2012. Effect of pain management on immunization efficacy in mice. *J Am Assoc Lab Anim Sci* **51**:448–457.
109. Kotiw M, Morgan M, Taylor SM, Shiels IA. 2010. Detection of anti-TNFα activity in canine hyperimmune serum using a TNFα inhibition assay. *Vet Clin Pathol* **39**:46–52. <https://doi.org/10.1111/j.1939-165X.2009.00166.x>.
110. Lapointe TK, Basso L, Iftinca MC, Flynn R, Chapman K, Dietrich G, Vergnolle N, Altier C. 2015. TRPV1 sensitization mediates postinflammatory visceral pain following acute colitis. *Am J Physiol Gastrointest Liver Physiol* **309**:G87–G99. <https://doi.org/10.1152/ajpgi.00421.2014>.
111. Latremoliere A, Woolf CJ. 2009. Central sensitization: a generator of pain hypersensitivity by central neural plasticity. *J Pain* **10**:895–926. <https://doi.org/10.1016/j.jpain.2009.06.012>.
112. Laudenslager ML, Fleshner M, Hofstadter P, Held PE, Simons L, Maier SF. 1988. Suppression of specific antibody production by

- inescapable shock: stability under varying conditions. *Brain Behav Immun* 2:92–101. [https://doi.org/10.1016/0889-1591\(88\)90010-4](https://doi.org/10.1016/0889-1591(88)90010-4).
113. Lee YJ, Chuang YC. 2010. Ibuprofen augments proinflammatory cytokine release in a mouse model of *Vibrio vulnificus* infection. *Microbiol Immunol* 54:542–550. <https://doi.org/10.1111/j.1348-0421.2010.00249.x>.
 114. Lees P, Giraudel J, Landoni MF, Toutain PL. 2004. PK-PD integration and PK-PD modelling of nonsteroidal antiinflammatory drugs: principles and applications in veterinary pharmacology. *J Vet Pharmacol Ther* 27:491–502. <https://doi.org/10.1111/j.1365-2885.2004.00618.x>.
 115. Lees P, Landoni MF, Giraudel J, Toutain PL. 2004. Pharmacodynamics and pharmacokinetics of nonsteroidal antiinflammatory drugs in species of veterinary interest. *J Vet Pharmacol Ther* 27:479–490. <https://doi.org/10.1111/j.1365-2885.2004.00617.x>.
 116. Li D, Ren Y, Xu X, Zou X, Fang L, Lin Q. 2008. Sensitization of primary afferent nociceptors induced by intradermal capsaicin involves the peripheral release of calcitonin gene-related Peptide driven by dorsal root reflexes. *J Pain* 9:1155–1168. <https://doi.org/10.1016/j.jpain.2008.06.011>.
 117. Li H, Edin ML, Gruzdev A, Cheng J, Bradbury JA, Graves JP, DeGraff LM, Zeldin DC. 2013. Regulation of T helper cell subsets by cyclooxygenases and their metabolites. *Prostaglandins Other Lipid Mediat* 104:105:74–83. <https://doi.org/10.1016/j.prostaglandins.2012.11.002>.
 118. Li H, Li C, Zhang H, Zhang L, Cheng R, Li M, Guo Y, Zhang Z, Lu Z, Zhuang Y, Yan M, Gu Y, Feng X, Liang J, Yu X, Wang H, Yao Z. 2016. Effects of lidocaine on regulatory T cells in atopic dermatitis. *J Allergy Clin Immunol* 137:613–617.e5. <https://doi.org/10.1016/j.jaci.2015.07.039>.
 119. Li H, Luo Y, Xu Y, Yang L, Hu C, Chen Q, Yang Y, Ma J, Zhang J, Xia H, Li Y, Yang J. 2018. Meloxicam improves cognitive impairment of diabetic rats through COX2-PGE2-EPs-cAMP/pPKA Pathway. *Mol Pharm* 15:4121–4131. <https://doi.org/10.1021/acs.molpharmaceut.8b00532>.
 120. Lima GK, Zolini GP, Mansur DS, Freire Lima BH, Wischhoff U, Astigarraga RG, Dias MF, das Graças Almeida Silva M, Béla SR, do Valle Antonelli LR, Arantes RM, Gazzinelli RT, Báfica A, Kroon EG, Campos MA. 2010. Toll-like receptor (TLR) 2 and TLR9 expressed in trigeminal ganglia are critical to viral control during herpes simplex virus 1 infection. *Am J Pathol* 177:2433–2445. <https://doi.org/10.2353/ajpath.2010.100121>.
 121. Lin JJ, Du Y, Cai WK, Kuang R, Chang T, Zhang Z, Yang YX, Sun C, Li ZY, Kuang F. 2015. Toll-like receptor 4 signaling in neurons of trigeminal ganglion contributes to nociception induced by acute pulpitis in rats. *Sci Rep* 5:1–14. <https://doi.org/10.1038/srep12549>.
 122. Liu YM, Zhu SM, Wang KR, Feng ZY, Chen QL. 2008. Effect of tramadol on immune responses and nociceptive thresholds in a rat model of incisional pain. *J Zhejiang Univ Sci B* 9:895–902. <https://doi.org/10.1631/jzus.B0820039>.
 123. Lleo A, Galea E, Sastre M. 2007. Molecular targets of non-steroidal anti-inflammatory drugs in neurodegenerative diseases. *Cell Mol Life Sci* 64:1403–1418. <https://doi.org/10.1007/s00018-007-6516-1>.
 124. López-Armada MJ, Sanchez-Pernaute O, Largo R, Diez-Ortego I, Palacios I, Egido J, Herrero-Beaumont G. 2002. Modulation of cell recruitment by anti-inflammatory agents in antigen-induced arthritis. *Ann Rheum Dis* 61:1027–1030. <https://doi.org/10.1136/ard.61.11.1027>.
 125. López A, Aparicio N, Pazos MR, Grande MT, Barreda-Manso MA, Benito-Cuesta I, Vazquez C, Amores M, Ruiz-Perez G, Garcia-Garcia E, Beatka M, Tolon RM, Dittel BN, Hillard CJ, Romero J. 2018. Cannabinoid CB2 receptors in the mouse brain: relevance for Alzheimer's disease. *J Neuroinflammation* 15:1–11. <https://doi.org/10.1186/s12974-018-1174-9>.
 126. Low D, Nguyen DD, Mizoguchi E. 2013. Animal models of ulcerative colitis and their application in drug research. *Drug Des Devel Ther* 7:1341–1357.
 127. Lucas T, Waisman A, Ranjan R, Roes J, Krieg T, Muller W, Roers A, Eming SA. 2010. Differential roles of macrophages in diverse phases of skin repair. *J Immunol* 184:3964–3977. <https://doi.org/10.4049/jimmunol.0903356>.
 128. Luo Y, Kuang S, Li H, Ran D, Yang J. 2017. cAMP/PKA-CREB-BDNF signaling pathway in hippocampus mediates cyclooxygenase 2-induced learning/memory deficits of rats subjected to chronic unpredictable mild stress. *Oncotarget* 8:35558–35572.
 129. Machelska H, Stein C. 2000. Pain control by immune-derived opioids. *Clin Exp Pharmacol Physiol* 27:533–536. <https://doi.org/10.1046/j.1440-1681.2000.03287.x>.
 130. Mack VE, McCarter MD, Naama HA, Calvano SE, Daly JM. 1996. Dominance of T-helper 2-type cytokines after severe injury. *Arch Surg* 131:1303–1308. <https://doi.org/10.1001/archsurg.1996.01430240057007>.
 131. MacPherson BR, Pfeiffer CJ. 1978. Experimental production of diffuse colitis in rats. *Digestion* 17:135–150. <https://doi.org/10.1159/000198104>.
 132. Makarenkova VP, Bansal V, Matta BM, Perez LA, Ochoa JB. 2006. CD11b+/Gr-1+ myeloid suppressor cells cause t cell dysfunction after traumatic stress. *J Immunol* 176:2085–2094. <https://doi.org/10.4049/jimmunol.176.4.2085>.
 133. Makman MH. 1994. Morphine receptors in immunocytes and neurons. *Adv Neuroimmunol* 4:69–82. [https://doi.org/10.1016/S0960-5428\(05\)80002-6](https://doi.org/10.1016/S0960-5428(05)80002-6).
 134. Mapplebeck JC, Beggs S, Salter MW. 2016. Sex differences in pain: a tale of 2 immune cells. *Pain* 157 Suppl 1:S2–S6. <https://doi.org/10.1097/j.pain.0000000000000389>.
 135. Marik PE, Flemmer M. 2012. The immune response to surgery and trauma: Implications for treatment. *J Trauma Acute Care Surg* 73:801–808. <https://doi.org/10.1097/TA.0b013e318265cf87>.
 136. Marko ST, Little SF, Benton CG, Kelly R, Field AE, Laufer RS. 2014. Effect of analgesics on monoclonal antibody ascites production in mice administered upon recognition of pain. *ISRN Immunology* 2014:1–8. <http://dx.doi.org/10.1155/2014/350796>.
 137. Martín AR, Villegas I, Alarcón de la Lastra C. 2005. The COX2 inhibitor, rofecoxib, ameliorates dextran sulphate sodium induced colitis in mice. *Inflamm Res* 54:145–151. <https://doi.org/10.1007/s00011-004-1337-2>.
 138. Martín AR, Villegas I, La Casa C, Alarcón de la Lastra C. 2003. The cyclo-oxygenase-2 inhibitor, rofecoxib, attenuates mucosal damage due to colitis induced by trinitrobenzene sulphonic acid in rats. *Eur J Pharmacol* 481:281–291. <https://doi.org/10.1016/j.ejphar.2003.09.033>.
 139. Martín WJ, Patrick SL, Coffin PO, Tsou K, Walker JM. 1995. An examination of the central sites of action of cannabinoid-induced antinociception in the rat. *Life Sci* 56:2103–2109. [https://doi.org/10.1016/0024-3205\(95\)00195-C](https://doi.org/10.1016/0024-3205(95)00195-C).
 140. Martucci C, Panerai AE, Sacerdote P. 2004. Chronic fentanyl or buprenorphine infusion in the mouse: similar analgesic profile but different effects on immune responses. *Pain* 110:385–392. <https://doi.org/10.1016/j.pain.2004.04.020>.
 141. Mascagni P, Sabbatini V, Biordi L, Martinotti S, Allegretti M, Marullo A, Caselli G, Bertini R. 2000. R- and S-isomers of non-steroidal anti-inflammatory drugs differentially regulate cytokine production. *Eur Cytokine Netw* 11:185–192.
 142. McCarter MD, Mack VE, Daly JM, Naama HA, Calvano SE. 1998. Trauma-induced alterations in macrophage function. *Surgery* 123:96–101. [https://doi.org/10.1016/S0039-6060\(98\)70234-X](https://doi.org/10.1016/S0039-6060(98)70234-X).
 143. Meseguer V, Alpizar YA, Luis E, Tajada S, Denlinger B, Fajardo O, Manenschiijn JA, Fernandez-Pena C, Talavera A, Kichko T, Navia B, Sanchez A, Senaris R, Reeh P, Perez-Garcia MT, Lopez-Lopez JR, Voets T, Belmonte C, Talavera K, Viana F. 2014. TRPA1 channels mediate acute neurogenic inflammation and pain produced by bacterial endotoxins. *Nat Commun* 5:1–14. <https://doi.org/10.1038/ncomms4125>.
 144. Michelin MA, Figueiredo F, Cunha FQ. 2002. Involvement of prostaglandins in the immunosuppression occurring during experimental infection by *Paracoccidioides brasiliensis*. *Exp Parasitol* 102:170–177. [https://doi.org/10.1016/S0014-4894\(03\)00053-5](https://doi.org/10.1016/S0014-4894(03)00053-5).
 145. Michelin MA, Silva JS, Cunha FQ. 2005. Inducible cyclooxygenase released prostaglandin mediates immunosuppression in acute phase of experimental *Trypanosoma cruzi* infection. *Exp Parasitol* 111:71–79. <https://doi.org/10.1016/j.exppara.2005.05.001>.
 146. Miller RE, Belmadani A, Ishihara S, Tran PB, Ren D, Miller RJ, Malfait AM. 2015. Damage-associated molecular patterns

- generated in osteoarthritis directly excite murine nociceptive neurons through Toll-like receptor 4. *Arthritis Rheumatol* **67**:2933–2943. <https://doi.org/10.1002/art.39291>.
147. **Miller RJ, Jung H, Bhangoo SK, White FA.** 2009. Cytokine and chemokine regulation of sensory neuron function. *Handb Exp Pharmacol* **194**:417–449. https://doi.org/10.1007/978-3-540-79090-7_12.
148. **Milligan ED, Zapata V, Chacur M, Schoeniger D, Biedenkapp J, O'Connor KA, Verge GM, Chapman G, Green P, Foster AC, Naeve GS, Maier SF, Watkins LR.** 2004. Evidence that exogenous and endogenous fractalkine can induce spinal nociceptive facilitation in rats. *Eur J Neurosci* **20**:2294–2302. <https://doi.org/10.1111/j.1460-9568.2004.03709.x>.
149. **Moehrlen U, Schwoebel F, Reichmann E, Stauffer U, Gitzelmann CA, Hamacher J.** 2005. Early peritoneal macrophage function after laparoscopic surgery compared with laparotomy in a mouse model. *Surg Endosc* **19**:958–963. <https://doi.org/10.1007/s00464-004-2118-2>.
150. **Molina-Martínez LM, Gonzalez-Espinosa C, Cruz SL.** 2014. Dissociation of immunosuppressive and nociceptive effects of fentanyl, but not morphine, after repeated administration in mice: fentanyl-induced sensitization to LPS. *Brain Behav Immun* **42**:60–64. <https://doi.org/10.1016/j.bbi.2014.06.011>.
151. **Monibi FA, Dodam JR, Axiak-Bechtel SM, Amorim J, Zhang Y, Tsuruta K, Mann FA, DeClue AE.** 2015. Morphine and buprenorphine do not alter leukocyte cytokine production capacity, early apoptosis, or neutrophil phagocytic function in healthy dogs. *Res Vet Sci* **99**:70–76. <https://doi.org/10.1016/j.rvsc.2015.01.010>.
152. **Montilla-García Á, Tejada M, Perazzoli G, Entrena JM, Portillo-Salido E, Fernández-Segura E, Cañizares FJ, Cobos EJ.** 2017. Grip strength in mice with joint inflammation: A rheumatology function test sensitive to pain and analgesia. *Neuropharmacology* **125**:231–242. <https://doi.org/10.1016/j.neuropharm.2017.07.029>.
153. **Morisset V, Urban L.** 2001. Cannabinoid-induced presynaptic inhibition of glutamatergic EPSCs in substantia gelatinosa neurons of the rat spinal cord. *J Neurophysiol* **86**:40–48. <https://doi.org/10.1152/jn.2001.86.1.40>.
154. **Mousa SA, Machelska H, Schafer M, Stein C.** 2002. Immunohistochemical localization of endomorphin-1 and endomorphin-2 in immune cells and spinal cord in a model of inflammatory pain. *J Neuroimmunol* **126**:5–15. [https://doi.org/10.1016/S0165-5728\(02\)00049-8](https://doi.org/10.1016/S0165-5728(02)00049-8).
155. **Mundt S, Groettrup M, Basler M.** 2015. Analgesia in mice with experimental meningitis reduces pain without altering immune parameters. *ALTEX* **32**:183–189.
156. **Muñoz-Miralles J, Trindade BC, Castro-Córdova P, Bergin IL, Kirk LA, Gil F, Aronoff DM, Paredes-Sabja D.** 2018. Indomethacin increases severity of Clostridium difficile infection in mouse model. *Future Microbiol* **13**:1271–1281. <https://doi.org/10.2217/fmb-2017-0311>.
157. **Nagahisa A, Okumura T.** 2017. Pharmacology of grapiprant, a novel EP4 antagonist: receptor binding, efficacy in a rodent post-operative pain model, and a dose estimation for controlling pain in dogs. *J Vet Pharmacol Ther* **40**:285–292. <https://doi.org/10.1111/jvp.12349>.
158. **Nakamura K, Radhakrishnan K, Wong YM, Rockson SG.** 2009. Anti-inflammatory pharmacotherapy with ketoprofen ameliorates experimental lymphatic vascular insufficiency in mice. *PLoS One* **4**:1–7. <https://doi.org/10.1371/journal.pone.0008380>.
159. **Nelson CJ, Lysle DT.** 1998. Severity, time, and β -adrenergic receptor involvement in surgery-induced immune alterations. *J Surg Res* **80**:115–122. <https://doi.org/10.1006/jsre.1998.5429>.
160. **Nemeth CL, Miller AH, Tansey MG, Neigh GN.** 2016. Inflammatory mechanisms contribute to microembolism-induced anxiety-like and depressive-like behaviors. *Behav Brain Res* **303**:160–167. <https://doi.org/10.1016/j.bbr.2016.01.057>.
161. **Okayama M, Hayashi S, Aoi Y, Nishio H, Kato S, Takeuchi K.** 2007. Aggravation by selective COX1 and COX2 inhibitors of dextran sulfate sodium (DSS)-induced colon lesions in rats. *Dig Dis Sci* **52**:2095–2103. <https://doi.org/10.1007/s10620-006-9597-z>.
162. **Onaivi ES, Ishiguro H, Gong JP, Patel S, Perchuk A, Meozzi PA, Myers L, Mora Z, Tagliaferro P, Gardner E, Brusco A, Akinshola BE, Liu QR, Hope B, Iwasaki S, Arinami T, Teasenfiz L, Uhl GR.** 2006. Discovery of the presence and functional expression of cannabinoid CB2 receptors in brain. *Ann N Y Acad Sci* **1074**:514–536. <https://doi.org/10.1196/annals.1369.052>.
163. **Paccani SR, Boncristiano M, Olivieri C, D'Elios MM, Del Prete G, Baldari CT.** 2002. Nonsteroidal antiinflammatory drugs suppress T-cell activation by inhibiting p38 MAPK induction. *J Biol Chem* **277**:1509–1513. <https://doi.org/10.1074/jbc.M110676200>.
164. **Pace MC, Passavanti MB, De Nardis L, Bosco F, Sansone P, Pota V, Barbarisi M, Palagiano A, Iannotti FA, Panza E, Aurilio C.** 2018. Nociceptor plasticity: a closer look. *J Cell Physiol* **233**:2824–2838. <https://doi.org/10.1002/jcp.25993>.
165. **Page GG, Ben-Eliyahu S, Yirmiya R, Liebeskind JC.** 1993. Morphine attenuates surgery-induced enhancement of metastatic colonization in rats. *Pain* **54**:21–28. [https://doi.org/10.1016/0304-3959\(93\)90095-7](https://doi.org/10.1016/0304-3959(93)90095-7).
166. **Page GG, Blakely WP, Ben-Eliyahu S.** 2001. Evidence that post-operative pain is a mediator of the tumor-promoting effects of surgery in rats. *Pain* **90**:191–199. [https://doi.org/10.1016/S0304-3959\(00\)00403-6](https://doi.org/10.1016/S0304-3959(00)00403-6).
167. **Pandey R, Mousawy K, Nagarkatti M, Nagarkatti P.** 2009. Endocannabinoids and immune regulation. *Pharmacol Res* **60**:85–92. <https://doi.org/10.1016/j.phrs.2009.03.019>.
168. **Pera M, Nelson H, Rajkumar SV, Young-Fadok TM, Burgart LJ.** 2003. Influence of postoperative acute-phase response on angiogenesis and tumor growth: open vs. laparoscopic-assisted surgery in mice. *J Gastrointest Surg* **7**:783–790. [https://doi.org/10.1016/S1091-255X\(03\)00111-2](https://doi.org/10.1016/S1091-255X(03)00111-2).
169. **Perše M, Cerar A.** 2012. Dextran sodium sulphate colitis mouse model: traps and tricks. *J Biomed Biotechnol* **2012**:1–13. <https://doi.org/10.1155/2012/718617>.
170. **Peterson NC.** 2000. Behavioral, clinical, and physiologic analysis of mice used for ascites monoclonal antibody production. *Comp Med* **50**:516–526.
171. **Peterson NC, Nunamaker EA, Turner PV.** 2017. To treat or not to treat: the effects of pain on experimental parameters. *Comp Med* **67**:469–482.
172. **Pezzone MA, Dohanics J, Rabin BS.** 1994. Effects of footshock stress upon spleen and peripheral blood lymphocyte mitogenic responses in rats with lesions of the paraventricular nuclei. *J Neuroimmunol* **53**:39–46. [https://doi.org/10.1016/0165-5728\(94\)90062-0](https://doi.org/10.1016/0165-5728(94)90062-0).
173. **Qi J, Buzas K, Fan H, Cohen JJ, Wang K, Mont E, Klinman D, Oppenheim JJ, Howard OM.** 2011. Painful pathways induced by TLR stimulation of dorsal root ganglion neurons. *J Immunol* **186**:6417–6426. <https://doi.org/10.4049/jimmunol.1001241>.
174. **Quallo T, Gentry C, Bevan S, Broad LM, Mogg AJ.** 2015. Activation of transient receptor potential ankyrin 1 induces CGRP release from spinal cord synaptosomes. *Pharmacol Res Perspect* **3**:1–10. <https://doi.org/10.1002/prp2.191>.
175. **Randhawa PK, Singh K, Singh N, Jaggi AS.** 2014. A review on chemical-induced inflammatory bowel disease models in rodents. *Korean J Physiol Pharmacol* **18**:279–288. <https://doi.org/10.4196/kjpp.2014.18.4.279>.
176. **Rao P, Knaus EE.** 2008. Evolution of nonsteroidal anti-inflammatory drugs (NSAIDs): cyclooxygenase (COX) inhibition and beyond. *J Pharm Pharm Sci* **11**:81s–110s. <https://doi.org/10.18433/J3T886>.
177. **Rather LJ.** 1971. Disturbance of function (*functio laesa*): the legendary 5th cardinal sign of inflammation, added by Galen to the 4 cardinal signs of Celsus. *Bull N Y Acad Med* **47**:303–322.
178. **National Research Council (US) Committee on Methods of Producing Monoclonal Antibodies.** 1999. Monoclonal antibody production. Washington (DC): National Academies Press.
179. **Rigoni M, Trevisani M, Gazzieri D, Nadaletto R, Tognetto M, Cremonin C, Davis JB, Campi B, Amadesi S, Geppetti P, Harrison S.** 2003. Neurogenic responses mediated by vanilloid receptor-1 (TRPV1) are blocked by the high affinity antagonist, iodo-resiniferatoxin. *Br J Pharmacol* **138**:977–985. <https://doi.org/10.1038/sj.bjp.0705110>.
180. **Roth J, Hübschle T, Pehl U, Ross G, Gerstberger R.** 2002. Influence of systemic treatment with cyclooxygenase inhibitors on lipopolysaccharide-induced fever and circulating levels of cytokines and

- cortisol in guinea-pigs. *Pflugers Arch* **443**:411–417. <https://doi.org/10.1007/s004240100718>.
181. **Sacerdote P, Bianchi M, Gaspani L, Panerai AE.** 1999. Effects of tramadol and its enantiomers on Concanavalin-A induced-proliferation and NK activity of mouse splenocytes: involvement of serotonin. *Int J Immunopharmacol* **21**:727–734. [https://doi.org/10.1016/S0192-0561\(99\)00048-X](https://doi.org/10.1016/S0192-0561(99)00048-X).
 182. **Sacerdote P, Bianchi M, Manfredi B, Panerai AE.** 1997. Effects of tramadol on immune responses and nociceptive thresholds in mice. *Pain* **72**:325–330. [https://doi.org/10.1016/S0304-3959\(97\)00055-9](https://doi.org/10.1016/S0304-3959(97)00055-9).
 183. **Sacerdote P, Manfredi B, Bianchi M, Panerai AE.** 1994. Intermittent but not continuous inescapable footshock stress affects immune responses and immunocyte beta-endorphin concentrations in the rat. *Brain Behav Immun* **8**:251–260. <https://doi.org/10.1006/brbi.1994.1023>.
 184. **Saito O, Svensson CI, Buczynski MW, Wegner K, Hua XY, Code-luppi S, Schaloske RH, Deems RA, Dennis EA, Yaksh TL.** 2010. Spinal glial TLR4-mediated nociception and production of prostaglandin E(2) and TNF. *Br J Pharmacol* **160**:1754–1764. <https://doi.org/10.1111/j.1476-5381.2010.00811.x>.
 185. **Samsam M, Covenas R, Csillik B, Ahangari R, Yajeya J, Riquelme R, Narváez JA, Tramu G.** 2001. Depletion of substance P, neurokinin A and calcitonin gene-related peptide from the contralateral and ipsilateral caudal trigeminal nucleus following unilateral electrical stimulation of the trigeminal ganglion; a possible neurophysiological and neuroanatomical link to generalized head pain. *J Chem Neuroanat* **21**:161–169. [https://doi.org/10.1016/S0891-0618\(01\)00088-6](https://doi.org/10.1016/S0891-0618(01)00088-6).
 186. **Sandoval BA, Robinson AV, Sulaiman TT, Shenk RR, Stellato TA.** 1996. Open versus laparoscopic surgery: a comparison of natural antitumoral cellular immunity in a small animal model. *Am Surg* **62**:625–630, discussion 630–621.
 187. **Sano T, Utsumi D, Amagase K, Matsumoto K, Tominaga M, Higuchi K, Takeuchi T, Kato S.** 2017. Lafutidine, a histamine H2 receptor antagonist with mucosal protective properties, attenuates 5-fluorouracil-induced intestinal mucositis in mice through activation of extrinsic primary afferent neurons. *J Physiol Pharmacol* **68**:79–90.
 188. **Schlosburg JE, Kinsey SG, Lichtman AH.** 2009. Targeting fatty acid amide hydrolase (FAAH) to treat pain and inflammation. *AAPS J* **11**:39–44. <https://doi.org/10.1208/s12248-008-9075-y>.
 189. **Schmelzer TM, Heath JJ, Hope WW, Mostafari A, Novitsky YW, Heniford BT.** 2008. The effect of preoperative corticosteroids on peritoneal macrophage function after laparoscopic and open abdominal surgery in a rat model. *Am J Surg* **196**:920–924, discussion 924–925. <https://doi.org/10.1016/j.amjsurg.2008.07.023>.
 190. **Scholz J, Woolf CJ.** 2007. The neuropathic pain triad: neurons, immune cells and glia. *Nat Neurosci* **10**:1361–1368. <https://doi.org/10.1038/nn1992>.
 191. **Serra MF, Anjos-Valotta EA, Olsen PC, Couto GC, Jurgilas PB, Cotias AC, Pao CR, Ferreira TP, Arantes AC, Pires AL, Cordeiro RS, Silva PM, Martins MA.** 2012. Nebulized lidocaine prevents airway inflammation, peribronchial fibrosis, and mucus production in a murine model of asthma. *Anesthesiology* **117**:580–591. <https://doi.org/10.1097/ALN.0b013e31826687d5>.
 192. **Shavit Y, Fridel K, Beilin B.** 2006. Postoperative pain management and proinflammatory cytokines: animal and human studies. *J Neuroimmune Pharmacol* **1**:443–451. <https://doi.org/10.1007/s11481-006-9043-1>.
 193. **Shavit Y, Martin FC, Yirmiya R, Ben-Eliyahu S, Terman GW, Weiner H, Gale RP, Liebeskind JC.** 1987. Effects of a single administration of morphine or footshock stress on natural killer cell cytotoxicity. *Brain Behav Immun* **1**:318–328. [https://doi.org/10.1016/0889-1591\(87\)90034-1](https://doi.org/10.1016/0889-1591(87)90034-1).
 194. **Shientag LJ, Wheeler SM, Garlick DS, Maranda LS.** 2012. A therapeutic dose of ketoprofen causes acute gastrointestinal bleeding, erosions, and ulcers in rats. *J Am Assoc Lab Anim Sci* **51**:832–841.
 195. **Singh VP, Patil CS, Jain NK, Kulkarni SK.** 2004. Aggravation of inflammatory bowel disease by cyclooxygenase-2 inhibitors in rats. *Pharmacology* **72**:77–84. <https://doi.org/10.1159/000079135>.
 196. **Smith RL, Kajiyama G, Schurman DJ.** 1997. Staphylococcal septic arthritis: antibiotic and nonsteroidal antiinflammatory drug treatment in a rabbit model. *J Orthop Res* **15**:919–926. <https://doi.org/10.1002/jor.1100150619>.
 197. **Srinath AI, Walter C, Newara MC, Szigethy EM.** 2012. Pain management in patients with inflammatory bowel disease: insights for the clinician. *Therap Adv Gastroenterol* **5**:339–357. <https://doi.org/10.1177/1756283X12446158>.
 198. **Stachtari CC, Thomareis ON, Tsaousi GG, Karakoulas KA, Chatzimanoli FI, Chatzopoulos SA, Vasilakos DG.** 2016. Interaction of a cannabinoid-2 agonist with Tramadol on nociceptive thresholds and immune responses in a rat model of incisional pain. *Am J Ther* **23**:e1484–e1492. <https://doi.org/10.1097/MJT.0000000000000131>.
 199. **Stein C, Clark JD, Oh U, Vasko MR, Wilcox GL, Overland AC, Vanderah TW, Spencer RH.** 2009. Peripheral mechanisms of pain and analgesia. *Brain Res Rev* **60**:90–113. <https://doi.org/10.1016/j.brainresrev.2008.12.017>.
 200. **Stein C, Hassan AH, Przewlocki R, Gramsch C, Peter K, Herz A.** 1990. Opioids from immunocytes interact with receptors on sensory nerves to inhibit nociception in inflammation. *Proc Natl Acad Sci USA* **87**:5935–5939. <https://doi.org/10.1073/pnas.87.15.5935>.
 201. **Stein C, Küchler S.** 2013. Targeting inflammation and wound healing by opioids. *Trends Pharmacol Sci* **34**:303–312. <https://doi.org/10.1016/j.tips.2013.03.006>.
 202. **Stills HF Jr.** 2005. Adjuvants and antibody production: dispelling the myths associated with Freund's complete and other adjuvants. *ILAR J* **46**:280–293. <https://doi.org/10.1093/ilar.46.3.280>.
 203. **Sun WZ, Chang MC, Hsiao PN, Chen CA, Hsu YT, Hsieh CY, Cheng WF.** 2010. Morphine-sparing effect by COX1 inhibitor sustains analgesic function without compromising antigen-specific immunity and antitumor effect of naked DNA vaccine. *Int J Immunopathol Pharmacol* **23**:91–104. <https://doi.org/10.1177/039463201002300109>.
 204. **Tai LH, de Souza CT, Belanger S, Ly L, Alkayyal AA, Zhang J, Rintoul JL, Ananth AA, Lam T, Breitbach CJ, Falls TJ, Kirn DH, Bell JC, Makriganis AP, Auer RA.** 2013. Preventing postoperative metastatic disease by inhibiting surgery-induced dysfunction in natural killer cells. *Cancer Res* **73**:97–107. <https://doi.org/10.1158/0008-5472.CAN-12-1993>.
 205. **Tai LH, Tanese de Souza C, Sahi S, Zhang J, Alkayyal AA, Ananth AA, Auer RA.** 2014. A mouse tumor model of surgical stress to explore the mechanisms of postoperative immunosuppression and evaluate novel perioperative immunotherapies. *J Vis Exp* **85**:1–7. <https://doi.org/10.3791/51253>.
 206. **Tajti J, Vecsei L.** 2009. [The mechanism of peripheral and central sensitization in migraine. A literature review] *Neuropsychopharmacol Hung* **11**:15–21. [Article in Hungarian].
 207. **Thau-Zuchman O, Shohami E, Alexandrovich AG, Trembovler V, Leker RR.** 2012. The antiinflammatory drug carprofen improves long-term outcome and induces gliogenesis after traumatic brain injury. *J Neurotrauma* **29**:375–384. <https://doi.org/10.1089/neu.2010.1673>.
 208. **Treede RD.** 2016. Gain control mechanisms in the nociceptive system. *Pain* **157**:1199–1204. <https://doi.org/10.1097/j.pain.0000000000000499>.
 209. **Üceyler N, Schäfers M, Sommer C.** 2009. Mode of action of cytokines on nociceptive neurons. *Exp Brain Res* **196**:67–78. <https://doi.org/10.1007/s00221-009-1755-z>.
 210. **Vachon P, Moreau JP.** 2002. Butorphanol decreases edema following carrageenan-induced paw inflammation in rats. *Contemp Top Lab Anim Sci* **41**:15–17.
 211. **Van Der Wal S, Vaneker M, Steegers M, Van Berkum B, Kox M, Van Der Laak J, Van Der Hoeven J, Vissers K, Scheffer GJ.** 2015. Lidocaine increases the antiinflammatory cytokine IL10 following mechanical ventilation in healthy mice. *Acta Anaesthesiol Scand* **59**:47–55. <https://doi.org/10.1111/aas.12417>.
 212. **Verge GM, Milligan ED, Maier SF, Watkins LR, Naeve GS, Foster AC.** 2004. Fractalkine (CX3CL1) and fractalkine receptor (CX3CR1) distribution in spinal cord and dorsal root ganglia under basal and neuropathic pain conditions. *Eur J Neurosci* **20**:1150–1160. <https://doi.org/10.1111/j.1460-9568.2004.03593.x>.

213. **Volker D, Bate M, Gentle R, Garg M.** 2000. Oral buprenorphine is antiinflammatory and modulates the pathogenesis of streptococcal cell wall polymer-induced arthritis in the Lew/SSN rat. *Lab Anim* **34**:423–429. <https://doi.org/10.1258/002367700780387732>.
214. **Wadachi R, Hargreaves KM.** 2006. Trigeminal nociceptors express TLR-4 and CD14: a mechanism for pain due to infection. *J Dent Res* **85**:49–53. <https://doi.org/10.1177/154405910608500108>.
215. **Walker JS, Chandler AK, Wilson JL, Binder W, Day RO.** 1996. Effect of mu-opioids morphine and buprenorphine on the development of adjuvant arthritis in rats. *Inflamm Res* **45**:557–563. <https://doi.org/10.1007/BF02342227>.
216. **Watkins LR, Maier SF.** 2002. Beyond neurons: evidence that immune and glial cells contribute to pathological pain states. *Physiol Rev* **82**:981–1011. <https://doi.org/10.1152/physrev.00011.2002>.
217. **Watkins LR, Maier SF.** 2005. Immune regulation of central nervous system functions: from sickness responses to pathological pain. *J Intern Med* **257**:139–155. <https://doi.org/10.1111/j.1365-2796.2004.01443.x>.
218. **Weng TC, Chen CC, Toh HS, Tang HJ.** 2011. Ibuprofen worsens *Streptococcus pyogenes* soft tissue infections in mice. *J Microbiol Immunol Infect* **44**:418–423. <https://doi.org/10.1016/j.jmii.2011.04.012>.
219. **White FA, Bhargoo SK, Miller RJ.** 2005. Chemokines: integrators of pain and inflammation. *Nat Rev Drug Discov* **4**:834–844. <https://doi.org/10.1038/nrd1852>.
220. **Wilson RI, Nicoll RA.** 2001. Endogenous cannabinoids mediate retrograde signalling at hippocampal synapses. *Nature* **410**:588–592. <https://doi.org/10.1038/35069076>.
221. **Wirtz S, Neufert C, Weigmann B, Neurath MF.** 2007. Chemically induced mouse models of intestinal inflammation. *Nat Protoc* **2**:541–546. <https://doi.org/10.1038/nprot.2007.41>.
222. **Wirtz S, Popp V, Kindermann M, Gerlach K, Weigmann B, Fichtner-Feigl S, Neurath MF.** 2017. Chemically induced mouse models of acute and chronic intestinal inflammation. *Nat Protoc* **12**:1295–1309. <https://doi.org/10.1038/nprot.2017.044>.
223. **Wu FX, Bian JJ, Miao XR, Huang SD, Xu XW, Gong DJ, Sun YM, Lu ZJ, Yu WF.** 2010. Intrathecal siRNA against Toll-like receptor 4 reduces nociception in a rat model of neuropathic pain. *Int J Med Sci* **7**:251–259. <https://doi.org/10.7150/ijms.7.251>.
224. **Wyns H, Meyer E, Plessers E, Watteyn A, van Bergen T, Schauvliege S, De Baere S, Devreese M, De Backer P, Croubels S.** 2015. Modulation by gamithromycin and ketoprofen of in vitro and in vivo porcine lipopolysaccharide-induced inflammation. *Vet Immunol Immunopathol* **168**:211–222. <https://doi.org/10.1016/j.vetimm.2015.09.014>.
225. **Yang C, Chang H, Zhang T, Liang C, Li E.** 2015. Pre-emptive epidural analgesia improves post-operative pain and immune function in patients undergoing thoracotomy. *ANZ J Surg* **85**:472–477. <https://doi.org/10.1111/ans.12746>.
226. **Yang J, Zhao J, Nakaguchi T, Gregersen H.** 2009. Biomechanical changes in oxazolone-induced colitis in BALB/C mice. *J Biomech* **42**:811–817. <https://doi.org/10.1016/j.jbiomech.2009.01.028>.
227. **Yardeni IZ, Beilin B, Mayburd E, Levinson Y, Bessler H.** 2009. The effect of perioperative intravenous lidocaine on postoperative pain and immune function. *Anesth Analg* **109**:1464–1469. <https://doi.org/10.1213/ANE.0b013e3181bab1bd>.
228. **Zheng YQ, Wei W, Shen YX, Dai M, Liu LH.** 2004. Oral and nasal administration of chicken type II collagen suppresses adjuvant arthritis in rats with intestinal lesions induced by meloxicam. *World J Gastroenterol* **10**:3165–3170. <https://doi.org/10.3748/wjg.v10.i21.3165>.
229. **Zielińska M, Ben Haddou T, Cami-Kobeci G, Sałaga M, Jarmuż A, Padysz M, Kordek R, Spetea M, Husbands SM, Fichna J.** 2015. Anti-inflammatory effect of dual nociceptin and opioid receptor agonist, BU08070, in experimental colitis in mice. *Eur J Pharmacol* **765**:582–590. <https://doi.org/10.1016/j.ejphar.2015.09.021>.
230. **Zou WY, Guo QL, Cai J, Wang E, Yang HW, Xu DM, Wang YC.** 2008. [[Effect of intrathecal pumping tramadol on the immune function in rats with formalin pain]] *Zhong Nan Da Xue Xue Bao Yi Xue Ban* **33**:404–409.[Article in Chinese].